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ABSTRACT 
 
 
A chemical study on the total extract of the zoanthid Palythoa tuberculosa, collected 
from the Red Sea, resulted in the isolation of seven polyhydroxylated sterols viz: 
palysterols A-G, six of which are new. Their chemical structures were elucidated on the 
basis of their 1D and 2D NMR and MS spectroscopic data. Palysterols B and G 
demonstrated cytotoxic activity on three human cancer cell lines (MCF-7, HeLa, and HT-
29). Palysterol G, in particular, was able to induce apoptosis in breast adenocarcinoma 
(MCF-7) cells. 
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CHAPTER ONE                                                                                                       
INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Introduction  
The medicinal use of natural products (NPs) (i.e. secondary metabolites) of terrestrial 
plants, marine organisms, or any natural source has captured human’s interest throughout 
the ages. Interestingly, palaeoanthropological (the scientific study of human fossils) 
studies conducted by Solecki at the cave site of Shanidar (Northern Iraq) were able to 
uncover several pollen grains which were buried, presumably intentionally, in a grave 
containing the remains of a Neanderthal dating back to more than 60,000 years ago 
(Solecki, 1975). These pollen samples are known to have curative properties, as diuretics, 
stimulants, astringents as well as anti-inflammatory properties (Solecki, 1975). Moreover, 
the documented use of oils from Papaver somniferum (poppy juice) and Commiphora 
species (myrrh) dating back to 2600 BC has been written about in cuneiform scripts from 
Mesopotamia. These oils are still used today for treatment of coughs, colds and 
inflammation. Also, the Papyrus Ebers written in 1500 BC describes hundreds of drugs 
prepared from terrestrial plants in ancient Egypt (Cragg and Newman, 2005). The World 
Health Organization (WHO) estimates that 80% of the population in third world countries 
depend on folk medicine for medical treatment (Ahmad et al., 1998).  
 
However, proper scientific toxicological, microbial, pharmacological and chemical 
studies are needed to ensure the safe use of these alternative medicines (Nkunya et al., 
1990). NP chemists have been able to isolate and identify the chemicals or secondary 
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metabolites responsible for the biological effects of these natural sources. Morphine is the 
first drug isolated from a natural source, and the first to be sold commercially as well (Ji 
et al., 2009). Merck started marketing morphine in 1826 as an opioid analgesic drug. The 
German pharmacist Friedrich Wilhelm Sertürner was the first person to isolate this 
compound from opium in 1806 (Sertürner, 1806).  
 
Now NPs have become an integral part of modern drug manufacturing. A recent study 
looking into the sources of novel drugs identified between the period 1981 and 2010,  
shows that in the category of anticancer drugs alone, nearly half of the drug components 
used are either entirely from or derived from NPs (Newman and Cragg, 2012). The 
influence of NPs is even higher in other drug classes such as anti-infective drugs 
(Newman and Cragg, 2012). Well-known examples of NPs that are part of drugs 
currently in use include antibiotics (e.g. erythromycin and its derivatives, such as 
clarithromycin), immunosuppressive agents (e.g. cyclosporin A and FK 506), anticancer 
agents (e.g. paclitaxel and camptothecin and its derivatives, such as topotecan and 
irinotecan) and anticholesterolemic agents (e.g. lovastatin and its derivatives) (Hung et 
al., 1996). 
 
1.1.2 Background on marine natural products 
For many years chemists focused mainly on terrestrial plants as a source of NPs, while no 
attention was given to marine organisms. It was only around the mid 20
th
 century when 
marine inhabitants were investigated for their unique biological activities (Capon, 2010). 
Nonetheless, there is some evidence of the use of marine organisms in folk medicine, for 
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example, seaweed-based remedies were advocated by early Chinese pharmacopeia to 
treat numerous disorders like, pain, abscesses, menstrual difficulties and cancer 
(Ruggieri, 1976).  
 
Most of the studies on Marine Natural Products (MNPs) were focused on marine 
invertebrates. These animals are soft-bodied and sessile, lacking morphological defence 
mechanisms, such as shells, claws or spines to ward off predators, hence they have 
adopted more subtle means to safeguard themselves against the extremely hostile marine 
environment by producing secondary metabolites that act as a chemical defence system to 
ensure their survival. These secondary metabolites can deter other organisms from 
feeding on some of the marine invertebrates (Blunt et al., 2008). Moreover, these 
secondary metabolites can defend the organisms from infections or induce cell growth 
inhibition to protect the territory from competitors. Also, these chemicals can facilitate 
organisms’ feeding process by immobilizing prey (Capon, 2010). 
 
In general, the secondary metabolites isolated from marine organisms differ structurally 
from secondary metabolites present in their terrestrial counterparts (Capon, 2010). These 
marine secondary metabolites exhibit a unique structural skeleton with unusual carbon 
and heterocyclic skeletons (Capon, 2010). Of equal importance, marine organisms exhibit 
higher bioactivity compared to terrestrial organisms. A screening study conducted by the 
US National Cancer Institute (NCI) evaluating the cytotoxicity of NPs showed that 
approximately 2% of the tested marine samples exhibited significant cytotoxicity, 
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whereas less than 0.5% of the terrestrial samples showed similar activity (Munro et al., 
1999). 
 
On the other hand, MNPs tend to be highly sensitive to light, temperature, oxygen and pH 
levels (Capon, 2010). Consequently, special precautions must be taken during their 
isolation and characterization. Separation methods such as acid and base extraction or 
steam distillation used to isolate secondary metabolites from terrestrial plants cannot be 
applied in the isolation of MNPs (Capon, 2010).      
 
Moreover, the presence of MNPs at very low concentrations relative to the net weight of 
the organisms is a major challenge for MNP chemists. For instance, one metric tonne of 
the tunicate Ecteinascidia turbinate is required to isolate one gram of ecteinascidin-743, a 
promising anti-cancer compound (Mendola, 2000). Also, in order to isolate around 300 
mg of potent cytostatic halichondrins, one metric tonne of the sponge Lissodendoryx sp. 
is required (Hart et al., 2000).  
 
There are, however, numerous approaches that can be adopted to overcome the 
availability issue of the MNPs (Table 1.1). Ecteinascidin-743, for example, was produced 
through mariculture and semi-synthesis (Cuevas et al., 2000). Aplidin
R
 and Kahalalide F 
were also successfully produced by full chemical synthesis (Jou et al., 1997) (López-
Maciá et al., 2001). Furthermore, since microbial symbionts are suggested to be the true 
source of the secondary metabolites formulated within the organisms, it is possible to 
control and manipulate their biosynthetic pathways to harvest their metabolites. For 
 
 
 
 
6 
 
example, the anticancer Salinosporamide A, which was first isolated from the marine-
sediment actinomycete strain S. tropica (Fenical et al., 2009), was supplied by means of 
saline-fermentation (Montaser and Luesch, 2011). In addition, the utilization of genetic 
engineering can also be used to supply MNPs, especially in case of uncultivated marine 
bacteria. For instance, the gamma-proteobacterium Candidatus Endobugula sertula, 
which is a symbiont of the marine bryozoan Bugula neritina, was found to be the true 
source of the anticancer compound bryostatin 1 (Hildebrand et al., 2004), which was 
supplied through the costly aquaculture process. The genes responsible for the 
biosynthesis of bryostatin 1 were successfully identified and sequenced (Sudek et al., 
2007). Consequently, the cloning of the biosynthetic genes for bryostatin 1 and its 
heterologous expression (the expression of a gene or part of a gene in a host organism) 
can provide a more practical option for the compound’s supply (Molinski et al., 2009). 
 
Table 1.1:  Possible mechanisms to overcome the low supply of marine products (source: Jimeno et al., 
2004). 
 
• Mariculture:                Farming the organism in its natural milieu 
• Aquaculture:               Culture of the organism under artificial conditions 
• Hemi synthesis:          Use of a parent / related compound as the starting point followed by 
                                       a short / industrially effective synthetic process 
• Synthesis 
• Microbial fermentation 
• Genetic intervention 
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1.1.3 Background on cancer 
1.1.3.1 Definition of cancer 
Cancer results from the failure of cell cycle control, which allows mutated or injured cells 
to evade apoptosis (programmed cell death), leading to the uncontrolled accumulation of 
such cells with these defects (Story and Kodym 1998). These mutations usually occur in 
proto-oncogenes which can, upon mutation, promote tumour growth. In addition to proto-
oncogenes, mutations can also take place in tumour suppressor genes, which in turn 
would promote uncontrolled cell cycle progression, hence promoting abnormal cell 
growth (Vermeulen et al., 2003).  
1.1.3.2 Cancer statistics 
Cancer is considered as one of main causes of death in first-world countries. While in 
third-world countries it is regarded as the second highest cause of mortality (Jemal et al., 
2011).  
 
The GLOBOCAN 2012 (globocan.iarc.fr), which is a statistical report of incidence and 
fatality rate of cancer worldwide issued by the  International Agency for Research on 
Cancer (IARC), stated that in the year 2012 there were nearly 14.1 million new cancer 
cases worldwide, and around eight million deaths from cancer in the same year 
(globocan.iarc.fr). More than half of new cases and mortalities caused by cancer occurred 
in less developed countries. Compared to cervical and colon cancer, breast cancer was 
more frequent with over 1.6 million new cases worldwide, while colon cancer’s fatality 
rate was higher with 694,000 deaths (Table 1.2).  
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Table 1.2:  Number of reported cancer cases and deaths worldwide in 2012 according to IARC 
(globocan.iarc.fr). 
 
Region Number of new cases* Number of deaths* 
Overall Breast Colon Cervical Overall Breast Colon Cervical 
World 14090 1677 1361 528 8201 522 694 266 
More developed 
regions 
6076 
 
794 737 83 2878 198 333 35 
Less developed 
regions 
8014 883 624 445 5323 324 361 230 
*Numbers are in thousands.  
 
There is also an increase in mortality rate caused by cancer in South Africa (SA). 
According to a report issued in 2014 by Statistics South Africa (Stats SA) 
(http://beta2.statssa.gov.za/), the annual percentage of deaths caused by neoplasms in SA 
in 2011 reached 7.3% of total 505 803 deaths registered in the same year. This is a 1.4% 
increase compared to the percentage registered in 2008 of total 595 624 deaths counted 
(Figure 1.1).  
 
Figure 1.1: Death percentages caused by neoplasms in SA reported from the year 2008 to 2011. 
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1.1.3.3 Progression of cancer  
In contrast to single-gene diseases, cancer is considered a multi-gene, multi-step disorder. 
First, the progression of cancer is ‘initiated’ by a DNA mutation of one somatic cell, 
followed by another or multiple stages of different mutations leading to the ‘promotion’ 
of several other cancerous cells until a tumour mass is established (Hejmadi, 2010). The 
latter step may take months or years before eventually tumour mass ‘progresses’ all over 
the body (metastasis) contributing to a detectable cancer (Figure 1.2) (Hejmadi, 2010).  
 
Figure 1.2: The development of cancer from a single cell by undergoing multi-stage mutations (Alison, 
2001). 
 
 
This “initiation, promotion, and progression” (IPP) model was presented to understand 
the genetic structure of cancer (Kopelovich, 1982; Trosko, 2010). Still, it is difficult to 
determine the exact number of mutations needed or genes involved for a cancer to 
become clinically manifested. “The six hallmarks of cancer” was described by Hanahan 
and Weinberg (2000) to help to discriminate cancer cells from normal or healthy cells. 
The six major hallmarks of cancer detail the exact sequence of mutations that must occur 
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for the cells to develop into clinical detectable cancer. These hallmarks include (1) the 
potential of having unlimited replications, (2) having self-sufficient growth signals, (3) 
resistance to anti-growth signals, (4) the ability to elude apoptosis, (5) angiogenesis: 
ability to grow new blood vessels and (6) the capability to metastasize and attack other 
tissues (Hanahan and Weinberg, 2000). 
1.1.3.4 Metastasis of cancer 
Metastasis is a fatal process in which the tumour cells invade other parts of the body after 
they exceed the capacity of their original environment to support their growth. In 2003, 
Fidler proposed his hypothesis “seed and soil” to explain how metastasis proceeds, where 
cells or “seeds” abandon their original tumour site, use blood vessels to spread, attack 
other favourable tissues “soil” (Figure 1.3).  
 
 
Figure 1.3: The process of metastasis inside the body (Withrow and Vail, 2007). 
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Firstly, growing of the tumour in size occurs by consumption of nutrients through simple 
diffusion, followed by manufacturing and  secretion of angiogenic factors to build blood 
vessels, then invasion of the surrounding host stroma takes place, subsequently tumour 
cells escape into the circulation after detachment, these cells then get entrapped in the 
vessels beds of the distant organs, eventually extravasation occurs and the metastasis 
process is completed by the proliferation of the tumour cells within the attacked organ 
(Fidler, 2003) . 
1.1.3.5 Aetiology of cancer 
Although certain genetic factors (e.g. in retinoblastoma, familial adenomatosis coli, 
xeroderma pigmentosum and familial carcinoma syndrome) can predispose an individual 
to cancer (Demant, 2005), there are also environmental factors that can cause cancer. For 
instance, according to Hejmadi the prevalence of stomach cancer in Japan is 6-8 fold 
higher compared to the incidence rate in the USA. Yet, young Japanese migrants to USA 
follow the same incidence rate as the USA population (Hejmadi, 2010). This change in 
incidence rate can be attributed to the differences in environmental and lifestyle factors 
and highlight the effect of these factors on the development of cancer (Hejmadi, 2010). 
 
An unhealthy diet can also be a major contributing factor. For example, high fat and low 
fibre intake is linked to bowl, pancreatic, prostate and breast cancer (Hejmadi, 2010). 
Moreover, some infectious agents can cause cancer, such as viruses [hepatitis B virus 
(HBV), human immunodeficiency virus (HIV)] or bacteria like Helicobacter pylori in the 
case of stomach cancer (Hejmadi, 2010). In addition, exposure to sunlight and ultraviolet 
rays is also associated with increased risk of skin cancer (Hejmadi, 2010).  
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1.1.3.6 Marine natural products in cancer treatment 
Besides surgical approaches, chemotherapy and radiotherapy are the backbone of cancer 
treatment. Yet for their many limitations, there is a need to find alternative ways to treat 
cancer. Chemotherapy possesses narrow therapeutic index associated with significant 
toxicity and is more often counteracted by the development of resistance (Vanneman and 
Dranoff, 2012). Furthermore, radiation is limited for many reasons; (1) the resistance of 
many tumours is sometimes higher than the normal surrounding tissue, (2) lack of clear 
patho-anatomical borders in some of the tumours, (3) difficulty of adjusting the treatment 
dose (Orth et al., 2014).  
 
Through the discovery of new agents capable of creating new ways of killing tumour 
cells by means of altering cell signalling, cell division, energy metabolism, gene 
expression or affecting angiogenesis, scientists will be able to unveil tumour-specific 
treatments with minimal side effects and greater efficiency (Nagle et al., 2004). 
 
Many previously isolated MNPs were found to have cytotoxic effects. These effects may 
be attributed to the ecological evolutionary need that led to the formation of some sort of 
chemical defence (McClintock et al., 2001) as discussed in section 1.1.2. Currently, more 
than 30 MNPs and their derivatives are studied in clinical trials as possible anticancer 
agents (Newman and Cragg, 2014).  
 
The anticancer use of MNPs began in the middle of the last century with the isolation of 
spongouridine and spongothymidine (Figure 1.4) from the Caribbean sponge Cryptotheca 
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crypta by the American scientist Werner Bergmann (Jimeno et al., 2004). Unlike most 
compounds of that class, spongouridine and spongothymidine possessed arabinose 
residues instead of the ribose and deoxyribose. This discovery was followed by the 
development of the antiviral [arabinoadenine (Ara-A, Vidarabine)] and anticancer 
[arabinocytosine (Ara-C, Cytarabine)] agents (Figure 1.4) (Stonik, 2009). Cytarabine is 
known to affect DNA replication and synthesis by blocking DNA polymerase (Uemura et 
al., 1985). It is a well-known chemotherapeutic agent and has been in use for the past 
four decades. Cytarabine is also considered to be a drug of choice for the treatment of 
Hodgkin’s lymphoma, acute lymphoblastic leukaemia and chronic myelogenous 
leukaemia (Cohen, 1976). Recently it was found that a high dose of cytarabine can be 
used in treatment of acute myeloid leukaemia (Löwenberg, 2013). 
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Figure 1.4: Chemical structures of spongouridine (a), spongothymidine (b), Ara-A (c) and Ara-C (d). 
1.1.3.6.1 Ecteinascidin-743 (ET-743, Yondelis
™
) 
Ecteinascidin-743 (ET-743) (Figure 1.5) is a tetrahydroisoquinoline alkaloid, first 
isolated from the tunicate Ecteinascidia turbinate living in the waters of West Indies 
coral reefs and mangrove swamps in 1990 (Rinehart et al., 1990; Wright et al., 1990). 
ET-743 inhibits activated transcription without showing any effect on the constitutive 
transcription (Minuzzo et al., 2000), which improves the targeting of the compound 
towards the highly active dividing cancer cells in comparison to the normal cells which 
exhibit normal rates of transcription and translation.  ET-743 also prevents the tumour 
cells from becoming resistant to chemotherapy as it interferes with the gene that produces 
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P-glycoprotein (Kanzaki et al., 2002), which is a protein that induces resistance of cancer 
cells towards other anticancer drugs such as doxorubicin and taxanes. ET-743 does not 
cause cytotoxic side effects such as, hair loss, mucositis, neurotoxicity or diarrhoea 
associated with other anticancer drugs (Lopez Martin et al., 2002). The drug was 
developed by the Spanish marine pharmaceutical company (pharmaMar), and marketed 
as Yondelis
™
. In 2014, pharmaMar reported that the net sale of Yondelis
™ 
in the first 
quarter increased by 18% compared to the same period from the previous year, reaching 
almost 20 million euro (www.zeltia.com).  
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Figure 1.5: Chemical structure of ET-743. 
1.1.3.6.2 Eribulin mesylate 
In 1986, a very potent cytotoxic compound, halichondrin B (Figure 1.6) was isolated 
from the sponge Halichondria okadai (Hirata and Uemura., 1986). The compound was 
found to bind to tubulin on the same site as vinca-alkaloids applied in clinical treatment 
(Bai et al., 1991). The low yield of this compound from H. okadai limited further clinical 
evaluation. Moreover, due to the compound’s complex structure, chemical synthesis of 
this compound was also unattainable (Aicher et al., 1992). It was not until much later 
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when scientists were able to obtain 310 mg of halichondrin B from the sponge 
Lissodendoryx sp. produced by aquaculture (Munro et al., 1999), which enabled the 
initiation of preclinical studies with halichondrin B. A new simpler derivative, eribulin 
mesylate (Figure 1.6), was developed by the Japanese Eisai company in 2010, which was 
approved as anticancer drug and launched onto market under trade name Halaven
™ 
(www.eisai.com). According to the company’s reports, the drug recorded 10.9 billion yen 
sales in 2011 compared to 0.4 billion yen when it was released in 2010.   
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Figure 1.6: Chemical structures of halichondrin B (a) and its derivative eribulin mesylate (b). 
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1.1.3.6.3 Kahalalide F (KF)  
Kahalalide F (Figure 1.7) was isolated from the mollusc (sea slug) Elysia rufescens 
gathered from Hawaii (Hamann et al., 1996). Kahalalide F is a C75 cyclic tridecapeptide 
that contains unusual amino-acid residues, including a rare Z-dehydroaminobutyric acid 
(Molinski et al., 2009). The mollusc feeds on the green algae Bryopsis sp., which is 
believed to be the source of KF (Hamann et al., 1996). 
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Figure 1.7: Chemical structure of kahalalide F. 
 
KF exhibits both in vivo and in vitro cytotoxicity against several tumour models, such as 
colon, breast, non-small cell lung and prostate cancer (Faircloth et al., 2001). Mechanistic 
studies of KF shows that it acts on lysosomal membranes by disrupting them and in turn 
forms large vacuoles, this mechanism is considered  unique compared to other antitumor 
agents, which increase acidification of the intra-cellular space leading to apoptosis 
(Garcia-Rocha et al., 1996). 
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1.1.3.6.4 Didemnin B  
Dideminin B (Figure 1.8) is a cyclic depsipeptide isolated from the Caribbean tunicate 
Trididemnum solidum (Rinehart et al., 1981), it was the first MNP to be subjected to 
clinical trials. The depsipeptide showed strong antiproliferative effect against several 
human tumour cell lines in vitro. Mechanistically, it was found that it acts as GTP-
binding protein elongation factor (Nuijen et al., 2000). Phase I and phase II clinical trials 
were conducted for the compound. However, the trials were ceased as dideminin B 
exhibited high toxicity, low solubility, and a short lifespan (Newman and Cragg 2004). 
More research into marine invertebrates led to isolation of dihydrodidemnin B (Figure 
1.8) from the Mediterranean tunicate Aplidum albicans. Dihydrodidemnin B showed 
similar effect to didemnin B, but with lower toxicity and higher solubility. Currently, 
synthetically derived dehydrodidemnin B is being subjected to phase II clinical studies 
under trade name Aplidine
®
 (APL) (Menna, 2009). 
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Figure 1.8: Chemical structures of didemnin B (a) and dehydrodidemnin B (b). 
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1.1.3.7 Cell death mechanisms 
Irregular cell death is a common factor in many human diseases such as cancer, stroke 
and neurodegenerative disorders (Kepp et al., 2011). Hence the regulation of cell death is 
an important approach for effective therapeutic strategy. For instance, anticancer agents 
induce cell death (Brown and Attardi, 2005), whereas cytoprotective drugs are used to 
avoid cell death in case of stroke, myocardial infarction or neurodegenerative disorders 
(Degterev et al., 2005). Controlled cell death is a vital biological mechanism that takes 
part in various physiological processes within any living organisms. It sculpts organs or 
separate fingers and toes (Penaloza et al., 2006). It also eliminates body structures that 
are no longer needed such as the tail of a tadpole during amphibian metamorphosis (the 
process of transformation from an immature form to an adult form) (Penaloza et al., 
2006).  
 
Generally, there are three types of cell death mechanisms namely apoptosis, autophagy 
and necrosis. Apoptosis (type I cell death) is morphologically characterized by the 
condensation of both the nucleus and the cytoplasm of the cell in addition to the 
fragmentation of the DNA. It involves cell shrinkage, blebbing of plasma membrane and 
formation of apoptotic bodies containing nuclear or cytoplasmic material (Clarke, 1990). 
Autophagy (type II cell death) is defined as an intracellular self-defence mechanism 
through which the accumulation of damaged or unwanted components of any cell are 
recycled by their sequestration into autophagic vesicles that subsequently are eliminated 
through fusion with lysosomes (Amaravadi et al., 2011). Necrosis (type III cell death) is 
described by Penaloza and co-workers as uncontrolled death that occurs as a result of cell 
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injury, leading to lysis of the cell. In necrosis, the cell membrane burst, allowing the 
leakage of cellular contents. Unlike apoptosis or autophagy, necrosis triggers 
inflammatory response due to the release of intracellular material, including the invasion 
of mast, phagocytes and natural killer cells (Penaloza et al., 2006). Therefore, massive 
necrosis can be threatening to the organism and can contribute to autoimmune reaction 
(Penaloza et al., 2006). 
  
1.1.3.7.1 Apoptosis 
Apoptosis is Greek word which depicts the process of falling of leaves from trees or 
petals from flowers. The term was inspired by the release of apoptotic bodies from the 
apoptotic cells (Reed, 2000). Kerr and co-workers first introduced the term to the 
scientific community in 1972 (Kerr et al., 1972). Apoptosis is considered to be a 
programmed cell-suicide functioning to remove unwanted or irreversibly damaged cells. 
Apoptosis is an important factor in development, taking part in morphogenesis (the 
sculpting of the form of embryos) and in sexual differentiation (Jacobson et al., 1997). 
Apoptosis is also involved in the growth of the immune and nervous systems of our body 
(Ameisen, 2002). Moreover, apoptosis is crucial for tissue homeostasis cells (Ameisen, 
2002).   
 
Any alteration in the levels of apoptosis can lead to many disease states. For instance, 
increased levels of apoptosis can lead to Alzheimer’s disease (Honig and Rosenberg, 
2000) and is also implicated in HIV/AIDS (Badley et al., 1997). On the other hand, 
decreased levels of apoptosis can lead to the development of cancer (Hejmadi, 2010), and 
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can also contribute to inflammation, persistent infections and autoimmune diseases (Reed 
and Pellecchia, 2005). 
 
Apoptosis is initiated by highly complex mechanisms (Figure 1.9) which involve several 
pathways; extrinsic or death receptor, which can be activated by extracellular ligands, 
intrinsic or mitochondrial, which is activated by various extra and intracellular stresses 
such as DNA damage, hypoxia and accumulation of undesired proteins (Kumar and 
Robbins, 2007), and perforin/granzyme (A or B) pathways, which are signalled by the 
immune system cells (Elmore, 2007). These pathways activate a family of intracellular 
enzymes known as caspases (Cysteine Aspartyl specific Proteases) which are present as 
inactive forms in all animal cells (Reed, 2000). A specific initiator caspase (caspase-8, -9 
or -10) is activated by each pathway and consequently activate the executioner caspase-3, 
resulting in DNA fragmentation, degradation of cytoskeleton and nuclear protein of the 
cell leading to its death. Conversely, the granzyme A pathway acts in a caspase-
independent manner which induces single stranded DNA damage (Reed, 2000).  The 
final step of apoptosis is the fragmentation of the nucleus into numerous smaller 
fragments. These fragments are encapsulated by apoptotic bodies which -in contrast to 
non-apoptotic cells- have their phosphatidylserines in the outer leaflet of their plasma 
membrane (Kumar and Robbins, 2007). The relocation of phosphatidylserine to the outer 
layer of the plasma membrane of the apoptotic bodies acts as a death signal that allow 
macrophages to recognise the apoptotic cells/bodies resulting in the macrophages 
engulfing and destroying the apoptotic cell (Ameisen, 2002). 
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Figure 1.9:  A diagram showing the pathways of apoptosis (source: Elmore, 2007). 
 
In conclusion, apoptosis plays a key role in the prevention of cancer (Hejmadi, 2010). 
The ability to elude apoptosis is a common feature in the development of cancer in living 
cells (Hanahan and Weinberg, 2000). Therefore, the targeted activation of apoptosis in 
cancer cells is a feasible therapeutic strategy to treat cancer. Many MNPs were found to 
induce cell death via apoptosis (Nagle et al., 2004). Such therapeutic agents can target 
cancer with minimal toxicity to normal cells and without the initiation of inflammatory 
reaction that can be induced by necrosis (Nagle et al., 2004).      
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1.2 Literature review on Palythoa tuberculosa 
1.2.1 Taxonomy 
 
Kingdom:  Animalia 
Phylum:    Cnidaria 
Class:       Anthozoa 
Subclass:  Hexacorallia 
Order:     Zoantharia 
Suborder: Brachycnemina 
Family:     Sphenopidae    
Genus:       Palythoa 
Species:     Palythoa tuberculosa (Esper, 1791). 
 
1.2.2 Ecological background  
Zoanthids (Anthozoa: Hexacorallia: Zoantharia) are common shallow reef benthic 
organisms. Some zooxanthellate genera, such as Palythoa (family: Sphenopidae) and 
Zoanthus (family: Zoanthidae), are aggressive benthic competitors in specific 
environmental conditions (Suchanek and Green, 1981; Sebens, 1982). Species of the 
genera Zoanthus and Palythoa within the suborder Brachycnemina are usually dominant 
components of live reef cover, particularly on coral reef tops and reef edges (Burnett et 
al., 1997; Swain, 2010; Irei et al., 2011). Species of the genus Palythoa are colonial and 
commonly found in shallow coral reefs worldwide. 
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Presently, there are more than 100 nominal species of Palythoa cited in the literature 
(Reimer, 2014). Nonetheless, for the high levels of morphological variation within the 
species it is believed that the exact number is much lower (Burnett et al., 1997; Reimer et 
al., 2004). Morphologically, Palythoa sp. have their tentacles arranged in two rows 
around their oral disk, and are enclosed with sand detritus, with foreign materials 
constituting up to 65% of their body weight (Haywick & Mueller, 1997), which makes it 
resistant to strong wave energy (Suchanek and Green, 1981; Irei et al., 2011). 
 
The tropical zoanthid Palythoa tuberculosa (Esper, 1791) has been shown to form 
extensive mats in the shallow inter- and intra-tidal zones. Its wide Indo-Pacific 
distribution includes the reefs of Japan, Saipan (Micronesia), Indonesia, Madagascar, and 
the Red Sea (Reimer et al., 2006). P. tuberculosa is an active planktonivore (feeds on 
planktons) (Fabricius and Metzner, 2004). P. tuberculosa also hosts a generalist 
Symbiodinium type (Reimer et al., 2006; Hibino et al., 2013). Moreover, during 
bleaching events the species can survive via heterotrophy (Reimer, 1971a, b) which, 
unlike many other bleaching-susceptible anthozoans, allows them to have low mortality 
during bleaching events (Jiménez, 2001). 
 
There is an observable increase in the number of P. tuberculosa recently in the Gulf of 
Suez (Red Sea, Egypt), particularly at Ras Za’farana and Ras Muhammed (Sharm El-
Sheikh, Egypt), forming extensive rubber mats covering large areas of coral reefs and 
overgrowing the reef-building corals in these areas (Figure 1.10). The rapidly growing, 
encrusting form of P. tuberculosa causes massive damage to the coral reefs in the Gulf of 
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Suez and the Egyptian Red Sea coast. This increased coverage of P. tuberculosa may be 
attributed to the recent change in the environmental conditions along the Egyptian Red 
Sea coast. Ras Za’farana marine environment is characterized by strong wave energy, 
high turbidity and increased nutrient enrichment (Ali and Hamed, 2006), these stresses 
may be tolerated by P. tuberculosa (Irei et al. 2011) and give it a competitive advantage 
over the true corals. Furthermore, under increased anthropogenic stress, these reef 
communities may shift from corals-dominated reef to aggressive and rapidly growing 
benthic zoanthid P. tuberculosa. However, there is little information about the factors 
responsible for the rapid growth of P. tuberculosa in the Gulf of Suez in the recent years. 
Much work is needed to understand the relationship between the increased coverage of 
the benthic zoanthid P. tuberculosa and the changing environmental conditions. 
 
A                                                                     B  
 
 
                                                                
 
 
Figure 1.10: The zoanthid rubber mat P. tuberculosa dominating the benthic substrate and overgrowing the 
corals at Ras Za’farana, Gulf of Suez, Egypt. Depth ~ 1 to 5 m (A). And at Ras Muhammed, Sharm E-
Sheikh, Egypt. Depth ~ 3 to 5 m (B). 
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1.2.3 Chemical studies on the species P. tuberculosa 
Even before the chemistry of genus Palythoa was studied, it was well-known for its 
toxicity. In Hawai’i, the zoanthid was deeply incorporated in the Hawaiian people’s 
myths and legends, it was known as ‘limy-make-o-Hana’ which can be translated to 
deadly seaweed of Hana (Uemura, 2010). One of these stories was about a sacred pool 
containing seaweed which when applied to the soldiers’ spears will bring certain death to 
foes, the pool became a sacred place and it was told that a curse will fall on anyone who 
dare to enter the site (Uemura, 2010).  
 
A study conducted between 1965 and 1967 in the same area identified a new species P. 
toxica (Walsh and Bowers, 1971). Subsequently, another study by Moore and Scheuer 
(1971) on P. toxica led to isolation of Palytoxin (PLTX) (Figure 1.11), which is one of 
the most toxic NP ever discovered (Pettit et al., 1982a). PLTX’s intravenous LD50 on 
dogs, rabbits, monkeys, guinea pigs, rats, and mice ranges between 0.033 and 0.45 µg/kg 
(Wiles et al., 1974).  By extrapolation, its toxic dose in humans was predicted to be in the 
range of 2.3 to 31.5 µg (Uemura, 1991).  Being a large molecule, PLTX was first 
reported to have a molecular weight of 3300 and molecular formula of C145H264N4O78 
with no repetition of sugar or amino acid units (Moore and Scheuer, 1971).  
 
In 1973, a study conducted on the gut content of filefish Aluterus scriptus in Japan 
revealed the presence of P. tuberculosa and a compound of similar character to PLTX 
(Kimura and Hashimoto, 1973). In his article published in 2010, Uemura stated that his 
group started working on the Okinawan P. tuberculosa in 1974 and was successful in 
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isolating PLTX which was found to be amphipathic (water and fat soluble) and was 
found to be 50 times more toxic than tetrodotoxin (one of the most powerful marine 
toxin) (Uemura, 2010). The 263 nm chromophore part (Figure 1.11) of the compound 
was identified by means of spectroscopy, chemical degradation and synthesis (Moore et 
al., 1975). A later study showed, using mass spectrometric analysis, that the exact 
molecular weight of PLTX was 2,681 and its molecular formula is C129H222N3O54 with 
eight double bonds (Macfarlane et al., 1980).  
 
Researchers continued their efforts to elucidate PLTX’s outstandingly large structure.  
Two different research groups proposed a planar structure for PLTX. A Japanese group 
studied the PLTX isolated from the Okinawan P. tuberculosa and reported a hydroxyl 
substituent at C44 and a hemiketal functionality at C47 (Figure 1.11) (Uemura et al., 
1981a and 1981b), whereas the chemical study of the compound isolated from a Palythoa 
sp. collected from Tahiti by Moore and Bartolini (1981) reported a ketal bond between 
C44 and C47 (Figure 1.11). PLTX’s stereostructure was described a year later (Klein et 
al., 1982; Ko et al., 1982; Fujioka et al., 1982; Cha et al., 1982). 
 
In 1984, it was shown that PLTX induces both coronary artery contraction and peripheral 
vessel contraction by easing the absorption of sodium ions by neurons (Muramatsu et al., 
1984 and 1988). It was also found that PLTX was not an antagonist to tetrodotoxin, 
suggesting the existence of a yet unidentified sodium channel (Muramatsu et al., 1984 
and 1988). It was later suggested that Na
+
, K‏+-ATPase was the target molecule and it was 
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proposed that a channel structure existed within the ion pump. This channel structure was 
later confirmed (Artigas and Gadsby, 2003).  
 
The cytotoxic action of PLTX was also studied. PLTX was found to control murine 
Ehlich ascites carcinoma in mice at a dose of 84 ng/kg (Quinn et al., 1974). The 
inhibitory effect of PLTX on the tumour was observed at doses as low as 5.25 ng/kg 
(Quinn et al., 1974), but the extreme toxicity of the compound hindered its usefulness as 
an anticancer agent. 
 
Further studies on P. tuberculosa led to the isolation of several PLTX-like compounds. In 
1985, homopalytoxin, bishomopalytoxin, neopalytoxin and deoxypalytoxin were isolated 
(Uemura et al., 1985). Ostreocin-D (Ukena et al., 2001) and ovatoxin-A (Ciminiello et 
al., 2012) are also PLTX-like structures which were isolated from the dinoflagellates 
Ostreopsis sp. In 2009, a new PLTX analogue, 42-hydroxypalytoxin (Figure 1.11), was 
isolated from both P. toxica and P. tuberculosa collected off the Hawaiian coast. The 
analogue showed similar biological activity to the PLTX (Ciminiello et al., 2009). 
Secondary metabolites like PLTX which are derived from marine sources and contain 
long carbon chains were named “super-carbon-chain compounds” (Uemura, 2006).  
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Figure 1.11: Chemical structure of PLTX*.  
 
*The figure illustrates a) Chromophore part of 263 nm, b) The part of PLTX reported by Uemura et al. 
(1981) showing hydroxyl substituent at C44 and a hemiketal functionality at C47, c) The part of PLTX 
showing the keton bond between C44 and C47 which was reported by Moore and Bartolini (1981), d) The 
part of PLTX showing the hydroxyl group at C42 in the reported structure of 42-hydroxypalytoxin by 
Ciminiello et al. (2009). 
 
Several other water-soluble compounds (Figure 1.12) with strong absorption maxima 
were successfully isolated in several studies conducted on P. tuberculosa; mycosporine-
Gly (Ito and Hirata, 1977), palythine (Takano et al., 1978a), palythinol and palythene 
(Takano et al., 1978b). These compounds, named mycosporine like amino acids or MAA, 
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are wildly spread among marine inhabitants and believed to protect these organisms 
against UV radiation (Dunlap and Chalker, 1986). MAAs, in particular mycosporine-Gly, 
were found to have moderate antioxidant activity which may suggest their role as photo-
oxidative stress protection caused by oxygen radicals in photoautotrophic symbiosis 
(Dunlap and Yamamoto, 1995). 
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Figure 1.12: Chemical structures of mycosporine-Gly (a), palythine (b), palythinol (c), and palythene (d). 
 
Further studies on P. tuberculosa led to the isolation of two isomeric compounds 
containing pyrazine rings; palythazine and isopalythazine (Figure 1.13). These 
compounds were found to be optically active and share the same molecular formula 
C12H16N2O4 (Uemura et al., 1979). The structures of these compounds were confirmed by 
means of chemical derivatization. 
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b  
Figure 1.13: Chemical structures of palythazine (a) and isopalythazine (b). 
 
In 1969, Gupta and Sheuer reported the isolation of a mixture of sterols from P. 
tuberculosa (Gupta and Sheuer, 1969). The physical constant of the sterol mixture was 
found to be similar to previously isolated sterol from P. mamnzilosa by Bergmann and 
co-workers in 1951 (Bergmann et al., 1951). Bergmann’s sterol was different from all 
other sterols identified at that time, and was thus given the name palysterol (Bergmann et 
al., 1951). The major sterol identified by Gupta and Sheuer was 22,23-
dihydrobrassicasterol (24β-methylcholest-5-en-3β-ol) (Figure 1.14), which had never 
before been identified from marine or natural source (Gupta and Sheuer, 1969). The other 
minor sterols were 24β-methylcholesta-5,22-dien-3β-ol, cholest-5-en-3β-ol, 24-
ethylcholest-5-en-3β-ol and gorgosterol (Figure 1.14) (Gupta and Sheuer, 1969). 
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Figure 1.14: Chemical structures of 24β-methylcholesta-5,22-dien-3β-ol (a), cholest-5-en-3β-ol (b), 24β-
methylcholest-5-en-3β-ol (c), 24-ethylcholest-5-en-3β-ol (d) and gorgosterol (e). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
33 
 
1.2.4 Chemical studies on the genus Palythoa 
Several studies conducted on Palythoa liscia, collected from Mauritius, were successful 
in isolating various anticancer agents. Petit and co-worker (1982a) isolated three cell 
growth inhibitor proteins with a higher mass than PLTX, namely palystatin 1 (mol. wt. 
128,000 ± 12,000), palystatin 2 (mol. wt. 5×10
5
) and palystatin 3 (mol. wt. > 2×10
7
). The 
three proteins exhibited anticancer activity when tested against murine P388 lymphocytic 
leukaemia, both palystatin 2 and 3 showed similar results (ED50 0.01 μg/ml) where 
palystatin 1 exhibited higher potency (ED50 1.3-5.5×10
-4
 μg/ml) (Pettit et al., 1982a).  
 
The same group also reported the isolation of several lower molecular weight peptides 
from the same species named ‘palystatin A-D’ of molecular weights 4,500, 4,000, 3,300 
and 3,000, respectively. The peptides exhibited anticancer activity and with ED50 values 
of 0.0023 (palystatin A), 0.020 (palystatin B), 0.0018 (palystatin C) and 0.022 μg/ml 
(palystatin D) (Pettit et al., 1982b).  
 
In the same year, Pettit and Fujii (1982) reported the isolation of several glycerol ethers 
from the same species. Two of these glycerols were pure; 1-O-hexadecylglycerol (chimyl 
alcohol) and l-O-octadecylglycerol (batyl alcohol) (Figure 1.15). Batyl alcohol, in 
particular, was reported to have anti-inflammatory effects similar to that of 
hydrocortisone, to accelerate wound healing and afford protection against radiation 
sickness (Pettit and Fujii, 1982). 
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CH2OH
CHOH
CH2OCH2(CH2)nCH3
a) n = 14 
b) n = 16  
Figure 1.15: Chemical structures of chimyl alcohol (a) and batyl alcohol (b). 
 
The chemical study of the phospholipids of the Puerto Rican zoanthid Palythoa 
caribaeorum revealed the presence of a new brominated fatty acid; 6-bromo-5,9-
eicosadienoic acid (Figure 1.16), along with several ∆5,9 fatty acids; 5,9-octadecadienoic 
acid, 5,9-eicosadienoic acid, 5,9-docosadienoic acid and 5,9-tetracosadienoic acid. This 
study proved that phospholipid fatty acids were not only confined to marine sponges as 
previously suggested (Carballeira and Reyes, 1995).  
 
Also, two new ectasteroids, palythoalones A and B (Figure 1.16), were isolated and 
identified by spectroscopic and chemical means from the methanolic extract of P. 
australiae collected from Okinawa (Shigemori et al., 1999).  
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Figure 1.16: Chemical structures of 6-bromo-5,9-eicosadienoic acid (a), palythoalones A (b) and 
palythoalones B (c). 
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1.3 Statement of research problem 
For many decades the oceans and seas drew the attention of biologists and chemists for 
the search of marine natural products formulated within the inhabitants of these vast and 
harsh environments. The chemical and biological nature of marine natural products is 
expected to be unique and different from natural products isolated from terrestrial 
sources. This uniqueness can mainly be attributed to the aqueous nature of the 
surroundings that the marine organisms find themselves in. Sessile creatures such as soft 
corals, sponges and zoanthids, had to develop alternative ways to protect their existence 
from predators and diseases. These organisms may therefore produce secondary 
metabolites with very unique cytotoxic activities. Cytotoxic natural products are 
important lead compounds for the discovery of new anticancer agents. 
 
Several chemical studies of the genus Palythoa (Coelenterata, Zoanthidae) and in 
particular the species of P. tuberculosa led to the isolation of several unique compounds. 
Many of these compounds have been shown to be extremely cytotoxic. However, no 
previous studies have been conducted on P. tuberculosa collected from Red sea. It is well 
known that there is a link between geographical location and both bio- and chemo-
diversity. It is therefore possible that chemical composition of P. tuberculosa collected 
from Red sea could be different from P. tuberculosa collected from other locations. 
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1.4 Problem identification 
What type of secondary metabolites exists within the P.tuberculosa collected from Red 
Sea? How can we isolate them? Are these metabolites cytotoxic and if they are cytotoxic 
can they induce apoptosis in human cancer cells? 
1.5 Research aim  
The aim of this study is to perform both chemical and biological characterization of the 
marine zoanthoid P. tuberculosa. The selected specimen will be extracted using suitable 
polar organic solvents. The extract will then be subjected to different chromatographic 
techniques using both simple [Thin Layer Chromatography (TLC) and Open Column 
Chromatography] and advanced chromatography [High Pressure Liquid Chromatography 
(HPLC)]. Subsequently, the isolated compounds will be investigated to determine their 
chemical structures using several spectroscopic techniques including, 1D and 2D NMR 
and MS. The purified compounds will undergo cytotoxicity evaluations using 
colorimetric in vitro assays on various human cancer cell lines.  
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Outline of Chapter Two: Chemical study of Palythoa tuberculosa 
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CHAPTER TWO  
CHEMICAL STUDY OF Palythoa tuberculosa 
 
2.1 Abstract 
The chemistry of P. tuberculosa attracted the attention for its structurally complex and 
highly toxic content, in particular PLTX. Red Sea is a unique marine source which 
contains highly diversified marine fauna including P. tuberculosa. Neither chemical nor 
biological studies have been conducted on P. tuberculosa growing in the Red Sea. These 
factors provided the justification to chemically and biologically evaluate the constituents 
of the P. tuberculosa from the Red Sea. The chemical study of P. tuberculosa resulted in 
the isolation of seven polyhydroxlated sterols viz; 24-methylenecholest-5-ene-1α,3β,11α-
triol (palysterol A), 24-methylenecholest-5-ene-1α,3β,11α,18-tetrol-1-acetate (palysterol 
B), 24-methylene-1α,3β,11α-trihydroxycholest-5-en-18-al-1-acetate (palysterol C), 
cholesta-5,22(23),24(28)-trien-1α,3β,11α-triol (palysterol D), cholesta-5,22(23),24(28)-
trien-1α,3β,11α-triol 1-acetate (palysterols E), cholesta-5,22(23),24(28)-trien-
1α,3β,11α,18-tetrol1,18-diacetate (palysterol F), and cholesta-5,22(23),24(28)-trien-
1α,3β,11α,trihydroxy-18-al 1-acetate (palysterols G). The presence of polyhydroxlated 
sterols in P. tuberculosa was reported early in 1961 as mentioned in section 1.2.3. In this 
study, no compounds related to PLTX were detected as indicated by the extensive NMR 
measurements of the different main fractions obtained from the methanolic extract of P. 
tuberculosa.  This chemical difference highlights the effect of the environmental and 
ecological factors on determining the chemical contents of P. tuberculosa. 
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2.2 Methodology of chemical isolation 
2.2.1 Reagents and solvents  
Ethanol................................................................................... Crest Chemicals (SA) 
Methanol................................................................................ Crest Chemicals (SA) 
Hexane................................................................................... Crest Chemicals (SA) 
Ethyl acetate........................................................................... Kimix (SA) 
Dichloromethane.................................................................... Kimix (SA) 
Sulphuric acid........................................................................ Kimix (SA)  
Deuterated chloroform........................................................... Merck, Germany  
Vanillin.................................................................................  Merck-Schuchardt, Germany. 
 
2.2.2 Solvent evaporation 
Rotavapor model Buchi Rotavapor RE 111 was used for solvent evaporation at 40 ᵒC and 
14 mbar. 
 
2.2.3 Chromatography 
2.2.3.1 Thin layer chromatography (TLC) 
Pre-coated plates of silica gel 60 F254 (Merck, Germany) was used for TLC analysis. 
Visualization of TLC plates was done by observing the bands “spots” under UV at λ254 
nm and λ366 nm using UV lamp (CAMAG, Switzerland), and by spraying with the 
vanillin/sulphuric acid reagent according to Wagner et al., (1984). 
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2.2.3.2 Column chromatography  
Glass columns (different diameters) packed with either silica gel 60 (0.063-0.0200 mm) 
(Merck), or alumina (Aluminium oxide Fluka typ 507C from Fluka AG, Buchs SG, 
Switzerland) were used for column chromatography. Size-exclusion chromatography was 
carried out using Sephadex
®
 LH-20 (Pharmacia). 
2.2.3.3 High Pressure Liquid Chromatography (HPLC)  
Sample purification was carried out using Agilent Technologies 1200 series, equipped 
with UV detector, manual injector, quaternary pump (G1311A), vacuum degasser 
(G1322A), column compartment (G1316A) (all experiments were done at room 
temperature) and reversed phase C18 column SUPELCO (25 x 1 cm, 5 μm). The flow rate 
was set at 1.5 mL/min. 
 
2.2.4 Spectroscopy 
2.2.4.1 Nuclear magnetic resonance (NMR) spectroscopy 
NMR spectra were recorded at 25 
o
C, using CDCl3 as solvent, on a Varian SYSTEM 500 
NMR spectrometer (
1
H 500 MHz, 
13
C 125 MHz) equipped with a 5-mm HCN cold probe. 
Chemical shifts of 
1H (δH) and 
13C (δC) in ppm were determined relative to 
tetramethylsilane. 
2.2.4.2 Mass spectroscopy (MS) 
High resolution mass spectroscopy (HRMS) analysis were conducted using an Agilent 
1200 LC binary pump coupled to an Agilent QTOF. Accurate Mass mass spectrometer 
using electrospray ionization (ESI) interface working in the positive mode. 
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2.2.4.3 Infrared (IR) spectroscopy 
Attenuated total internal reflectance FTIR measurements were carried out using Spectrum 
100 (PerkinElmer). Spectra recording were accomplished using the interface “Spectrum”. 
Dicholoromethane was used to dissolve the samples.  
2.2.4.4 Optical rotation measurements 
Optical activity measurements were conducted using Anton Paar MCP 200 Polarimeter. 
The following conditions were used: sample concentration: 0.1g/mL in dichloromethane; 
wavelength: 589 nm; cell temperature: 25 
o
C.   
2.3 Sample collection and identification  
The Red Sea Palythoa tuberculosa was collected in May 2010, at depth of 2-3 meters 
from Hurghada, Egypt. The tissue was kept in MeOH. The material was collected by Dr. 
A. Ali (National Institute of Oceanography and Fisheries, Suez City, Egypt) and 
identified by Dr. S. Parker-Nance (Zoology department, Nelson Mandela Metrpolitan 
University) and Dr. A. Ali. A voucher specimen is kept at Institute of Oceanography and 
Fisheries (Suez, Egypt). 
2.4 Extraction of the marine sample 
The fresh sliced bodies of ~1.0 kg of the collected species were blended with MeOH. The 
extract was filtered using Whatman filter paper, the residue was washed twice with fresh 
MeOH. The total extract was concentrated under vacuum and partitioned between EtOAc 
and H2O. The water fraction was dried and the residue was washed with methanol and 
combined to the EtOAc fraction. 
 
 
 
 
 
43 
 
2.5 Fractionation of the total extract 
The extract (20 g) was applied to silica gel column (5 x 30 cm) and eluted using mixture 
of hexane/EtOAc/methanol (Table 2.1). 
 
Table 2.1: Solvent system used for fractionation of the total extract of P. tuberculosa. 
 
Solvent volume Solvent system Fractions 
collected 
1 L Hexane 1-4 
1 L Hexane : Ethyl acetate   95:5 5-8 
1 L Hexane : Ethyl acetate  90:10 9-12 
1 L Hexane : Ethyl acetate  85:15 13-16 
2 L Hexane : Ethyl acetate  80:20 17-24 
1 L Hexane : Ethyl acetate  75:25 25-28 
2 L Hexane : Ethyl acetate  70:30 29-36 
1 L Hexane : Ethyl acetate  65:35 37-40 
2 L Hexane : Ethyl acetate  60:40 41-48 
1 L Hexane : Ethyl acetate   55:45 49-52 
2 L Hexane : Ethyl acetate   50:50 53-60 
1 L Hexane : Ethyl acetate   40:60 61-64 
1 L Hexane : Ethyl acetate   30:70 65-68 
1 L Hexane : Ethyl acetate   20:80 69-72 
1 L Hexane : Ethyl acetate   10:90 73-76 
1 L Ethyl acetate 100% 77-80 
1 L Ethyl acetate : Methanol   95:5 81-84 
1 L Ethyl acetate : Methanol  80:20 85-88 
1 L Ethyl acetate : Methanol  50:50 89-92 
1.5 L Methanol  100 % 93 
 
93 different fractions (volume = 250 mL) were collected. The fractions were concentrated 
on the rota-evaporator and chromatographed on TLC plates using different solvent 
systems; hexane:EtOAc 9:1 and DCM:MeOH 5%. The fractions were pooled together 
according to their TLC profiles (Figures 2.1) and were designated roman numbers (Table 
2.2). 
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Table 2.2: Fractions obtained upon fractionation of the total extract of P.tuberculosa. 
 
Fractions 
collected 
Designated 
number 
Fractions 
collected 
Designated 
number 
Fractions 
collected 
Designated 
number 
1-4 I 37-38  XVI  77, 78  XXXI  
5-7 II 39-40  XVII  79-81  XXXII  
8-9 III 41-42  XVIII  82-83  XXXIII  
10 IV 43-45  XIX  84-85  XXXIV  
11 V 46-47  XX  86-88  XXXV  
12-14 VI 48-49  XXI  89-91  XXXVI  
15-16 VII 50-51  XXII  92-93  XXXVII  
17-19  VIII  52-53  XXIII  
20-22  IX  54-56  XXIV  
23-24  X  57-58  XXV  
25-27  XI  59-63  XXVI  
28-30  XII  64-68  XXVII  
31-32  XIII  69-70  XXVIII  
33-34  XIV  71-72  XXIX  
35-36  XV 73-76  XXX  
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Figure 2.1: TLC profile of the main fractions after spraying with H2SO4/vanillin (A, B and C) and under 
UV light (a, b and c). 
 
*TLC plate (A) of main fractions (I-XII) was developed using hexane:EtOAc 70:30 
*TLC plate (B) of main fractions (XII-XXIII) was developed using hexane:EtOAc 50:50 
*TLC plate (C) of main fractions (XXIII -XXXVI) was developed using DCM:MeOH 7%. 
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2.6 Isolation of the pure compounds 
 
2.6.1 Isolation of palysterols C, E and G. 
 
Main fraction XXII (100 mg) was adsorbed on silica gel and fractionated on an open 
column using gradient solvent system of hexane:EtOAc (80:20 to 0:100). The sub-
fractions collected were combined together according to the TLC profile (Figure 2.2). 
 
 
 
Figure 2.2: TLC of sub-fractions of main fraction XXII using DCM:MeOH 4% (double run) as mobile 
phase.  
 
sub-fraction XXII1 (Figure 2.2) was injected to the HPLC and eluted using gradient 
solvent system of MeOH and de-ionized water (DIW) (90:10 to 100% MeOH in 20 min, 
then 100% MeOH for 10 min). The peak at 25.5 min (Figure 2.3) was collected and gave 
palysterol E (1.8 mg). The sub-fraction XXII2 (Figure 2.2) was also injected to the HPLC 
and eluted using gradient solvent system of MeOH:DIW (85:15 to 95:5 in 20 min, then 
95:5 to 100% MeOH in 15 min). Two quantifiable peaks, at 25.2 and 27.1 min (Figure 
2.4), were collected. The first peak gave palysterol G (6.6 mg). While the second peak 
(XXII2-1) (41.6 mg) was injected to the HPLC using gradient solvent system of 
MeOH:DIW (90:10 to 100% MeOH in 10 min). The peak at 16.9 min (Figure 2.5) was 
collected and gave palysterol C (30 mg). 
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Figure 2.3: HPLC chromatogram of sub-fraction XXII1
*
. 
*Conditions: 
Solvent  MeOH:DIW 90:10 to 100% MeOH in 20 min 
Column  SUPELCO, RP18 (25X2.1 cm) 
Flow rate 1.5 mL/min 
Detection  UV at 220 nm 
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Figure 2.4: HPLC chromatogram of sub-fraction XXII2
*
. 
*Conditions: 
Solvent  MeOH:DIW (85:15 to 95:5 in 20 min, then from 95:5 to 100% MeOH in 15 
min) 
Column  SUPELCO, RP18 (25X2.1 cm) 
Flow rate 1.5 mL/min 
Detection  UV at 220 nm 
 
 
 
Figure 2.5: HPLC chromatogram of sub-fraction XXII2-1
*
. 
*Conditions: 
Solvent  MeOH:DIW (90:10 to 100% MeOH in 10 min) 
Column  SUPELCO, RP18 (25X2.1 cm) 
Flow rate 1.5 mL/min 
Detection  UV at 220 nm 
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2.6.2 Isolation of palysterol F 
Main fraction XXV (90 mg) was injected to the HPLC and eluted using gradient solvent 
system of MeOH:DIW (80:20 to 85:15 in 20 min, then to 90:10 in 10 min, then to 100% 
MeOH in 10 min). The peak (XXV1) (20 mg), eluted at 32.2 min (Figure 2.6), was re-
injected to the HPLC using gradient solvent system of MeOH:DIW (80:20 to 85:15 in 5 
min, then to 95:5 in 30 min, then to 100% MeOH  in 5 min). The peak eluted at 37.3 min 
(Figure 2.7) was collected and gave palysterol F (6 mg).   
 
 
 
Figure 2.6: HPLC chromatogram of main fraction XXV
*
. 
*Conditions: 
Solvent  MeOH:DIW (80:20 to 85:15 in 20 min, then from 85:15 to 90:10 in 10 min, 
followed by increase to 100% MeOH in 10 min) 
Column  SUPELCO, RP18 (25X2.1 cm) 
Flow rate 1.5 mL/min 
Detection  UV at 220 nm 
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Figure 2.7: HPLC chromatogram of sub-fraction XXV1
*
. 
*Conditions: 
Solvent  MeOH:DIW (80:20 to 85:15 in 5 min, then to 95:5 in 30 min, followed by 
increase to 100% MeOH  in 5 min) 
Column  SUPELCO, RP18 (25X2.1 cm) 
Flow rate 1.5 mL/min 
Detection  UV at 220 nm 
 
 
2.6.3 Isolation of palysterol B 
Main fraction XXVI (300 mg) was adsorbed on alumina and fractionated on an open 
column and eluted using gradient solvent system of DCM/MeOH of increasing polarity 
(0 to 10% MeOH). The sub-fractions were concentrated and developed in a TLC plate. 
The sub-fraction XXVI1 (100 mg) (Figure 2.8) was adsorbed on silica gel and 
fractionated on a column using solvent system of hexane:EtOAc (55:45). Sub-fraction 
XXVI1-1 (46 mg) was collected from the column and injected to the HPLC using gradient 
solvent system of MeOH:DIW (80:20 to 100% MeOH in 30 min). The peaks eluted from 
30.0 to 35.5 min (Figure 2.9) were collected and gave Palysterol B (5.3 mg). 
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Figure 2.8: Collective TLC of main fraction XXVI, developed using DCM:MeOH 6%.   
 
 
 
 
Figure 2.9: HPLC chromatogram of sub-fraction XXVI1-1. 
*Conditions: 
Solvent  MeOH:DIW (80:20 increasing to 100% MeOH in 30 minutes) 
Column  SUPELCO, RP18 (25X2.1 cm) 
Flow rate 1.5 mL/min 
Detection  UV at 220 nm 
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2.6.4 Isolation of palysterol A and D 
Main fraction XXVII (188 mg) was adsorbed on alumina oxide and fractionated on an 
open column using gradient solvent system of DCM:MeOH (from 0.1% DCM to 3%). 
The sub-fraction XXVII1 (35 mg) was collected and then injected to the HPLC using 
gradient solvent system of MeOH:DIW (80:20 to 100% MeOH in 30 min) to give 
palysterol D (3.8 mg) at 36.9 min and palysterol A (3.5 mg) at 38.7 min (Figure 2.10). 
 
 
 
Figure 2.10: HPLC chromatogram of sub-fraction XXVII1
*
. 
*Conditions: 
Solvent  MeOH:DIW (80:20 to 100% MeOH in 30 min) 
Column  SUPELCO, RP18 (25X2.1 cm) 
Flow rate 1.5 mL/min 
Detection  UV at 220 nm 
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   Palysterol E (1.8 mg)                                Palysterol F (6 mg)              XXVI1-1 
                                                                                                                                                                                                
                                                                                                                                                                                     HPLC fractionation 
                                                                                                                                           
 
 
 
    Palysterol G (6.6 mg)          XXII2-1                                                        Palysterol B (5.3 mg) 
                                            
                                                         HPLC fractionation 
                                                                                              
 
         
 
                                           Palysterol C (30 mg)             Palysterol D (3.8 mg)         Palysterol A (3.5 mg) 
 
 
 
Scheme 2.1: A flow diagram for the isolated compounds from P. tuberculosa. 
*All HPLC fractionations were done using different mixtures of MeOH:DIW. 
 
 
 
 
 
 
 
 
Total extract of  
P. tuberculosa 
 
 
 
 
54 
 
2.7 Spectroscopic data of the isolated compounds  
 
Palysterol A: white, amorphous powder; IR: 3308, 3054, 2942, 2305, 1640, 1421, 1265, 
1051, 896, 739, 705 cm
-1
; 
1
H NMR (CDCl3) and 
13
C NMR (CDCl3): see table 2.3. HRMS 
m/z 430.3462 [M]
+ 
(calcd for C28 H46 O3, 430.3447). 
Palysterol B: white, amorphous powder; [α]25D -1.5 (c 0.1, DCM); IR: 3054, 2305, 1422,  
1265, 1050, 895, 739, 705 cm
-1
; 
1
H NMR (CDCl3) and 
13
C NMR (CDCl3): see table 2.3. 
HRMS m/z 488.3510 [M]
+ 
(calcd for C30 H48 O5, 488.3502). 
Palysterol C: white, amorphous powder; [α]25D -2.5 (c 0.1, DCM); IR: 3944, 3424, 3054, 
2962, 2305, 1713, 1421, 1375, 1265, 1049, 896, 739, 705 cm
-1
; 
1
H NMR (CDCl3) and 
13
C 
NMR (CDCl3): see table 2.3. HRMS m/z 486.3357 [M]
+ 
(calcd for C30 H46 O5, 486.3345). 
Palysterol D: white, amorphous powder; [α]25D -14 (c 0.1, DCM); IR: 3945, 3691, 3054, 
2986, 2305,  1421, 1265, 896, 735, 705 cm
-1
; 
1
H NMR (CDCl3) and 
13
C NMR (CDCl3): 
see table 2.3. HRMS m/z 428.3309 [M]
+ 
(calcd for C28 H44 O3, 428.3290). 
Palysterol E: white, amorphous powder; [α]25D -9 (c 0.1, DCM); IR: 3054, 2986, 2305, 
1421, 1265, 896, 753, 705 cm
-1
; 
1
H NMR (CDCl3) and 
13
C NMR (CDCl3): see table 2.3. 
HRMS m/z 470.3417 [M]
+ 
(calcd for C30 H46 O4, 470.3396). 
Palysterol F: white, amorphous powder; [α]25D 10.5 (c 0.1, DCM); IR: 3944, 3690, 3599, 
3054, 2986, 2685, 2410, 2305, 1731, 1604, 1421, 1375, 1265, 1143, 1053,1019, 896, 735, 
705 cm
-1
; 
1
H NMR (CDCl3) and 
13
C NMR (CDCl3): see table 2.3. HRMS m/z 528.3451 
[M]
+ 
(calcd for C32 H48 O6, 528.3451). 
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Palysterol G: white, amorphous powder; [α]25D 18 (c 0.1, DCM); IR: 3463, 3054, 2985, 
2305, 1719, 1422, 1374, 1265, 1051, 896, 739, 705 cm
-1
; 
1
H NMR (CDCl3) and 
13
C 
NMR (CDCl3): see table 2.3. HRMS m/z 484.3193 [M]
+ 
(calcd for C30 H44 O5, 484.3189). 
2.8 Results and discussion 
The isolated palysterols were fully characterized by 1D (
1
H and 
13
C) and 2D NMR 
experiments, including gCOSY, TOCSY, multiplicity-edited gHSQC and gHMBC.  
1
H 
and 
13
C NMR chemical shifts observed are summarized in table 2.3.  
 
2.8.1 Analysis of Palysterol A 
The molecular formula of Palysterol A (Figure 2.11) was determined by HRMS as C28 
H46 O3. The 
1
H NMR spectrum of palysterol A (Figure 2.12) exhibited the signals for five 
methyls at δ 1.03 (3H, d, J = 6.8 Hz, H-26), 1.02 (3H, d, J = 6.8 Hz, H-27), 0.96 (3H, d, J 
= 6.6 Hz, H-21), 1.13 (3H, s, H-19), and 0.67 (3H, s, H-18); an olefinic proton at δ 5.56 
(1H, td, J = 5.6, 2.0 Hz, H-6), a methylene terminal group at δ 4.71 and 4.65 (2H, brd, H-
28) and three oxygenated methines at δ 4.21 (1H, t, J = 3.3 Hz, H-1), 4.07 (1H, td, J = 
10.3, 5.6 Hz, H-11) and 3.97 (1H, tt, J = 11.6, 4.7 Hz,  H-3). The 
13
C NMR spectroscopic 
data (Figure 2.13) (Table 2.3) together with analysis of its multiciplity-edited gHSQC 
spectrum (Figure 2.15) indicated 28 carbons, including five methyls, ten methylenes (one 
olefinic), nine methines (three oxygenated and one olefinic), and four quaternary carbons 
(two olefinic). From the gHMBC spectrum correlations (Figures 2.16 and 2.17), the 
structure of this compound was fully established. The relative stereochemistry of 
palysterol A was mainly assigned by a ROESY spectrum. Relevant correlations showed, 
mainly between Me-19 (δ 1.13) and H-1 and H-11, and between H-4α (δ 2.65) and H-3, 
 
 
 
 
56 
 
as well as between Me-18 (δ 0.67) and H-8, H-11 and H-20. These led us to establish the 
structure as 24-methylenecholest-5-ene-1α,3β,11α-triol. The structure was confirmed by 
comparing the data with those published by Jagodzinska et al. (1985). 
4
1 9
1311
2220
24
26
28
27
HO
OH
HO
19
18
21
 
Figure 2.11: Chemical structure of palysterol A. 
 
 
 
Figure 2.12: 
1
H NMR (500 MHz, CDCl3) of palysterol A. 
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Figure 2.13: 
13
C NMR (125 MHz, CDCl3) of palysterol A. 
 
 
Figure 2.14: gCOSY (500 MHz, CDCl3) of palysterol A. 
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Figure 2.15: Multiplicity-edited gHSQC (methylene: blue cross peaks; methyl and methine: red cross peaks) (500 
MHz, CDCl3) of palysterol A. 
 
 
 
 
 
 
Figure 2.16: Selected gHMBC correlations observed for palysterol A. 
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Figure 2.17: gHMBC (500 MHz, CDCl3) of palysterol A. 
 
 
2.8.2 Analysis of palysterol B 
The NMR spectroscopic data (Figures 2.19 and 2.20) of palysterol B (C30 H48 O5) (Figure 
2.18) showed similar spectra with those of palysterol A. The 
13
C NMR data (Table 2.3) 
together with analysis of its multiciplity-edited gHSQC spectrum (Figure 2.22) indicated 
30 carbons, including five methyls, eleven methylenes (one oxygenated and one olefinic), 
nine methines (three oxygenated and one olefinic) and five quaternary carbons (two 
olefinic and one carbonyl carbons). The COSY spectrum (Figure 2.21) showed 
correlations between H-2/H-1 and H-3; H-11/H-12; and H-6/H-7. The only differences 
with palysterol A were the lack of the Me-18 resonance and the presence of an acetoxyl 
group (δH 2.05 s, 3H; δC 171.64 s and 21.55 q) and a new oxygenated-methylene group 
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(δH 3.59 s, 2H; δC 61.46 t). The gHMBC spectrum (Figures 2.23 and 2.24) showed, in 
essence, the same relevant correlations of palysterol A (Figure 2.17). New correlations 
between the acetoxy-carbonyl carbon and H-1 and between the oxygenated-methylene 
carbon and H-12, H-14 and H-17 were observed. Finally, the ROESY spectrum (Figure 
2.25) showed correlations between H-18 (δH 3.59) and H-8 (δH 1.45), H-11 (δH 3.99) and 
H-20 (δH 1.60). From the data above, the structure was identified as 24-methylenecholest-
5-ene-1α,3β,11α,18-tetrol 1-acetate. To the best of our knowledge, palysterol B was not 
isolated before from any other natural source.  
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Figure 2.18: Chemical structure of palysterol B. 
 
Figure 2.19: 
1
H NMR (500 MHz, CDCl3) of palysterol B. 
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Figure 2.20: 
13
C NMR (125 MHz, CDCl3) of palysterol B. 
 
Figure 2.21: gCOSY (500 MHz, CDCl3) of palysterol B. 
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Figure 2.22: Multiplicity-edited gHSQC (methylene: blue cross peaks; methyl and methine: red cross peaks) (500 
MHz, CDCl3) of palysterol B. 
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Figure 2.23: Selected gHMBC correlations observed for palysterol B. 
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Figure 2.24: gHMBC (500 MHz, CDCl3) of palysterol B. 
 
 
 
 
Figure 2.25: ROESY (500 MHz, CDCl3) of palysterol B. 
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2.8.3 Analysis of palysterol C 
The 
1
H and 
13
C NMR (Figures 2.27 and 2.28) spectra of palysterol C (C30 H46 O5) (Figure 
2.26) was similar to those of palysterol B. The disappearance of the Me-18 resonance and 
the presence of an acetoxyl group (δH 2.02 s, 3H; δC 171.74 s and 21.53 q). In addition, a 
new formyl group (δH 9.77 s, 2H; δC 206.45 d) was observed. The gHMBC spectrum 
(Figure 2.31) showed the same relevant correlations of those showed for palysterol A 
(Figure 2.17) as well as some new relevant correlations between the acetoxy carbonyl 
carbon and H-1 and between the formyl carbon and H-12, H-14 and H-17. The COSY 
spectrum (Figure 2.29) showed correlations between H-2/H-1 and H-3; H-11/H-12; and 
H-6/H-7. Finally, the ROESY spectrum (Figure 2.32) showed correlations between the 
aldehyde proton (δ 9.77) and H-8, H-11 and H-20. From the data above, the structure was 
identified as 24-methylene-1α,3β,11α-trihydroxycholest-5-en-18-al 1-acetate. To the best 
of our knowledge, palysterol C is isolated, in this study, for the first time from nature.  
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Figure 2.26: Chemical structure of palysterol C. 
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Figure 2.27: 
1
H NMR (500 MHz, CDCl3) of palysterol C. 
 
 
 
Figure 2.28: 
13
C NMR (125 MHz, CDCl3) of palysterol C. 
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Figure 2.29: gCOSY (500 MHz, CDCl3) of palysterol C. 
 
 
 
 
Figure 2.30: Multiplicity-edited gHSQC (methylene: blue cross peaks; methyl and methine: red cross peaks) (500 
MHz, CDCl3) of palysterol C. 
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Figure 2.31: gHMBC (500 MHz, CDCl3) of palysterol C. 
 
 
 
Figure 2.32: ROESY (500 MHz, CDCl3) of palysterol C. 
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2.8.4 Analysis of palysterol D 
The molecular formula of palysterol D (Figure 2.33) was determined by HRMS as 
C28H44O3. The 
13
C NMR spectroscopic data (Figure 2.35) (Table 2.3) together with 
analysis of its multiciplity-edited gHSQC spectrum (Figure 2.37) indicated 28 carbons, 
including five methyls, seven methylenes (one olefinic), twelve methines (three 
oxygenated and three olefinic) and four quaternary carbons (two olefinic). Its 1D NMR 
spectral data were similar to those of palysterol A except for the presence of two double 
bonds in the side-chain. The COSY spectrum (Figure 2.36) showed correlations between 
H-2/H-1 and H-3; H-11/H-12; H-6/H-7; and H-22/H-23 and H20. Additionally, the 
ROESY spectrum (Figure 2.40) showed correlations between Me-18/H-11, H-20 and H-
8. The key gHMBC (Figure 2.38) correlations of the vinylic protons (H-22) with C-17, 
C-20, C-21, C-24 and H-23 with C-20, C-24, C-25 and C-28, led to the placement of the 
two double bonds at C-22 and C-24 of the side-chain, respectively. Thus, the structure of 
the palysterol D was proposed as Cholesta-5,22(23),24(28)-trien-1α,3β,11α-triol. To the 
best of our knowledge, palysterol D is isolated, in this study, for the first time from 
nature. 
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Figure 2.33: Chemical structure of palysterol D. 
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Figure 2.34: 
1
H NMR (500 MHz, CDCl3) of palysterol D. 
 
 
Figure 2.35: 
13
C NMR (125 MHz, CDCl3) of palysterol D. 
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Figure 2.36: gCOSY (500 MHz, CDCl3) of palysterol D. 
 
 
Figure 2.37: Multiplicity-edited gHSQC (methylene: blue cross peaks; methyl and methine: red cross peaks) (500 
MHz, CDCl3) of palysterol D. 
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Figure 2.38: Selected gHMBC correlations observed for palysterol D. 
 
 
 
Figure 2.39: gHMBC (500 MHz, CDCl3) of palysterol D. 
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Figure 2.40: ROESY (500 MHz, CDCl3) of palysterol D. 
 
2.8.5 Analysis of palysterol E 
13
C NMR spectra (Figure 2.43) of palysterol E (C30 H46 O4) (Figure 2.41) displayed 30 
carbon signals. The 
1
H and 
13
C NMR (Figures 2.42 and 2.43) spectra of palysterol E are 
consistent with those of palysterol D (Table 2.3). The only significant difference was the 
presence of an acetoxyl group (δH 2.06 s, 3H; δC 171.71 s and 21.56 q). The COSY 
spectrum (Figure 2.44) showed correlations between H-2/H-1 and H-3; H-11/H-12; H-
6/H-7; and H-22/H-23 and H20. Additionally, the ROESY spectrum (Figure 2.47) 
showed correlations between Me-18/H-11, H-20 and H-8. The gHMBC correlation 
between the acetoxy carbonyl carbon and H-1 (δH 5.70) confirmed the position of the 
acetyl group on C-1 (Figure 2.46). From the data above, the structure was identified as 
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Cholesta-5,22(23),24(28)-trien-1α,3β,11α-triol 1-acetate. To the best of our knowledge, 
palysterol E was not isolated before from other natural sources.  
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Figure 2.41: Chemical structure of palysterol E. 
 
 
Figure 2.42: 
1
H NMR (500 MHz, CDCl3) of palysterol E. 
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Figure 2.43: 
13
C NMR (125 MHz, CDCl3) of palysterol E. 
 
Figure 2.44: gCOSY (500 MHz, CDCl3) of palysterol E. 
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Figure 2.45: Multiplicity-edited gHSQC (methylene: blue cross peaks; methyl and methine: red cross peaks) (500 
MHz, CDCl3) of palysterol E. 
 
Figure 2.46: gHMBC (500 MHz, CDCl3) of palysterol E. 
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Figure 2.47: ROESY (500 MHz, CDCl3) of palysterol E. 
 
2.8.6 Analysis of palysterol F 
Palysterol F (Figure 2.48) possessed the molecular formula C32H48O6, as determined by 
its HRMS. The 
13
C NMR spectroscopic data (Figure 2.50) (Table 2.3) together with 
analysis of its gHSQC spectrum (Figure 2.51) indicated 32 carbons, including six 
methyls, eight methylenes (one oxygenated and one olefinic), twelve methines (three 
oxygenated and three olefinic), and six quaternary carbons (two olefinic and two 
carbonyl carbons). The significant differences with D were the presence of two acetoxyl 
groups (δH 2.06 s, 3H; δC 171.87 s and 21.58 q) and (δH 2.10 s, 3H; δC 171.29 s and 21.17 
q) and of a new oxygenated-methylene group (δH 4.02, 3.96, 2H; δC 63.06 t). 
Comprehensive analysis of the gHMBC spectra (Figure 2.52) suggested that the two 
acetoxy groups were located on C-1 and C-18. In addition, the gHMBC correlations 
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between the oxygenated-methylene carbon and H-12/C-18, H-14/C-18 and H-17/C-18, 
combined with ROESY correlations between the methylene protons H-8, H-11 and H-20, 
confirmed the structure as Cholesta-5,22(23),24(28)-trien-1α,3β,11α,18-tetrol 1,18-
diacetate. To the best of our knowledge, palysterol F was not isolated before from other 
natural sources.  
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Figure 2.48: Chemical structure of palysterol F. 
 
Figure 2.49: 
1
H NMR (500 MHz, CDCl3) of palysterol F. 
 
 
 
 
 
78 
 
 
Figure 2.50: 
13
C NMR (125 MHz, CDCl3) of palysterol F. 
 
 
Figure 2.51: Multiplicity-edited gHSQC (methylene: blue cross peaks; methyl and methine: red cross peaks) (500 
MHz, CDCl3) of palysterol F. 
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Figure 2.52: gHMBC (500 MHz, CDCl3) of palysterol F. 
 
2.8.7 Analysis of palysterol G 
The molecular formula of palysterol G (Figure 2.53) was determined by HRMS as 
C30H44O5.  The 
13
C NMR spectroscopic data (Figure 2.55) (Table 2.3) together with 
analysis of its multiciplity-edited gHSQC spectrum (Figure 2.57) indicated 30 carbons, 
including five methyls, seven methylenes (one olefinic), thirteen methines (three 
oxygenated, three olefinic and one formyl carbon) and five quaternary carbons (two 
olefinic and one carbonyl carbons). The COSY spectrum (Figure 2.56) showed 
correlations between H-2/H-1 and H-3; H-11/H-12; H-6/H-7; and H-22/H-23 and H20. 
Additionally, the ROESY spectrum (Figure 2.59) showed correlations between Me-18/H-
11, H-20 and H-8. The 
1
H and 
13
C NMR (Figures 2.54 and 2.55) spectra of palysterol G 
are consistent with those of palysterol C (Table 2.3). The only significant difference was 
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the presence of extra double bond C-22/C-23 at 5.49 dd (δC 133.6) and 5.92 d (δC 
130.87). The presence of a formyl group (δH 9.77 s, 2H; δC 206.45 d), combined with the 
same gHMBC and ROESY correlations that those for palysterol C, confirmed the 
structure as Cholesta-5,22(23),24(28)-trien-1α,3β,11α,trihydroxy-18-al 1-acetate. To the 
best of our knowledge, palysterol G was not isolated before from other natural sources.  
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Figure 2.53: Chemical structure of palysterol G. 
 
 
 
Figure 2.54: 
1
H NMR (500 MHz, CDCl3) of palysterol G. 
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Figure 2.55: 
13
C NMR (125 MHz, CDCl3) of palysterol G. 
 
 
Figure 2.56: gCOSY (500 MHz, CDCl3) of palysterol G. 
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Figure 2.57: Multiplicity-edited gHSQC (methylene: blue cross peaks; methyl and methine: red cross peaks) (500 
MHz, CDCl3) of palysterol G. 
 
 
 
Figure 2.58: gHMBC (500 MHz, CDCl3) of palysterol G. 
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Figure 2.59: ROESY (500 MHz, CDCl3) of palysterol G. 
 
 
According to the literature, all the isolated compounds are new structures, except 
palysterol A, which was reported by Jagodzinska et al. (1985). However, those 
assignments were determined by comparison with other sterols with similar structure and 
configuration. 
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Table 2.3: 
1
H (500 MHz) and 
13
C (125 MHz) NMR spectral data of palysterols A-G*. 
 
 
 
 
Position A B C D E F G 
 13C 1H 13C 1H 13C 1H 13C 1H 13C 1H 13C 1H 13C 1H 
1 74.49 4.21 t (3.3) 78.13 5.70 dd (3.9, 2.2) 78.10 5.60 74.49 4.21 78.14 5.70 78.20 5.70 78.08 5.65 dd (4.0, 2.3) 
2 38.31 2.11, 
1.76 ddd(-13.0, 
11.6, 3.0) 
35.57 2.06, 
1.79 ddd (-13.9, 
11.6, 2.3) 
35.36 2.03, 
1.75 
38.30 2.11, 1.76 35.63 2.05, 1.80 35.64 2.04, 1.81 35.55 2.05, 
1.78 ddd (-13.9, 
11.5, 2.3) 
3 66.39 3.97 tt (11.6, 4.7) 66.75 3.90 66.53 3.86 66.38 3.97 66.78 3.91 66.73 3.91 66.65 3.89 
4 42.16 2.39 ddd (-12.3, 
5.0, 2.6), 
2.26 
41.58 2.39, 2.34 41.67 2.34- 2.31 42.15 2.40, 2.26 41.86 2.38- 2.37 41.82 2.39, 2.34 41.82 2.37- 2.34 
5 138.63  137.15  137.21  138.61 -- 136.97 -- 137.01 -- 137.22  
6 124.68 5.56 124.22 5.59 123.55 5.54 124.67 5.56 124.45 5.60 124.06 5.58 123.60 5.56 
7 32.46  1.99 dtt (-15.8, 
5.3, 2.7), 
1.68 
31.51 1.96, 
1.51 
30.55 2.03, 
1.53 
32.44  1.99, 1.67 31.20 1.95, 1.53 31.32 1.96, 1.51 31.21 2.05, 
1.55 
8 31.75 1.51 31.79 1.45 32.96 1.27 31.76 1.51 31.50 1.38 31.77 1.45 32.93 1.35 
9 48.23 1.66 48.78 1.25 48.16 1.25 48.27 1.67 49.04 1.26 49.03 1.20 48.41 1.25 
10 43.00  41.83  41.42  42.95 --- 43.08 -- 41.62 -- 41.52  
11 68.10 4.07 td (10.3, 5.6) 68.68 3.99 td (11.0, 4.2) 68.68 3.89 68.08 4.08 68.89 3.93 68.49 3.89 68.72 3.87 
12 50.72 2.33 dd (11.9, 5.6), 
1.26 
46.12 2.66 dd (-12.3, 
4.3), 
1.07 
44.50 2.75 dd (-12.4, 
4.7), 
1.11 
50.58 2.31, 1.28 51.01 2.26, 1.18 46.05 2.64, 1.14 44.28 2.77 dd (-12.3, 
4.6), 
1.16 
13 42.82  47.52  59.48  42.84 -- 41.56 -- 45.86 -- 59.34  
14 55.52 1.17 55.78 1.23 55.73* 1.50* 55.56 1.17 56.40* 1.08* 55.94 1.27 55.75* 1.50* 
15 24.27 1.62, 1.06 23.78 1.61, 1.01 24.32 1.85, 1.67 24.24 1.59, 1.04 23.93 1.55, 1.06 23.65 1.61, 1.03 24.26 1.85, 1.67 
16 28.35 1.91, 1.30 28.19 1.93, 1.43 29.14 2.18, 1.61 28.64 1.74, 1.30 28.59 1.70, 1.29 28.72 1.78, 1.39 28.65 2.03, 1.65 
17 55.63 1.20 56.12 1.27 55.64* 1.60* 55.61 1.28 55.70* 1.26* 55.94 1.38 55.66* 1.70* 
18 12.53 0.67 s 61.46 3.59 206.45 9.77 12.78 0.71 (s) 13.30 0.74 63.06 4.02, 3.96 206.45 9.77 
19 19.24 1.13 s 18.63  1.26 s 18.54  1.12 s 19.24 1.14 (s) 18.64 1.26 (s) 18.62  1.26 (s) 18.56  1.12 s 
20 35.61 1.40 35.98 1.60 36.34 1.36 40.26 2.11 40.28 2.10 40.95 2.08 40.37 2.14 
21 18.67 0.96 d (6.6) 19.25 1.07 d (6.4) 18.16 0.92 d (6.5) 20.49 1.07 (d) 20.37 1.06 (d) 20.68 1.15 (d) 20.29 1.07 d (6.7) 
22 34.57 1.54 ,1.15 34.66 1.52, 1.16 34.52 1.53, 1.13 135.42 5.56 135.58 5.54 (dd) 135.22 5.49 133.64 5.49 dd (15.7, 8.7) 
23 30.87 2.09, 1.87 30.59 2.08, 1.88 31.20 2.02, 1.83 129.50 5.94 129.39 5.93 (d) 129.66 5.93 130.87 5.92 d (15.8) 
24 156.65  156.77  156.09  152.89  152.92 -- 152.75 -- 152.49  
25 33.79 2.22 33.88 2.22 33.75 2.17 29.36 2.54 29.38 2.54 29.39 2.53 29.37 2.51 sept (6.8) 
26 21.85 1.03 21.86 1.02 21.77 0.97 22.03 1.06 22.38 1.06 22.03 1.07 22.09 1.06 
27 21.99 1.02 21.97 1.01 21.89 0.99 22.39 1.06 22.04 1.06 22.36 1.05 22.02 1.06 
28 106.04 4.71, 4.65 105.95 4.71, 4.65 106.24 4.71, 4.62 109.86 4.85,4.83 109.75 4.84, 4.82 110.02 4.85,4.83 110.64 4.86, 4.85 
OAc-1   21.55, 
171.64 
2.05 21.53, 
171.74 
2.02   21.56, 
171.71 
2.06 21.58, 
171.87 
2.06 21.53, 
171.74 
2.05 
OAc-18           21.17, 
171.29 
2.10   
* Measured in CDCl3 at 25ºC. Chemical shifts in ppm and coupling constants in Hz. 
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CHAPTER THREE  
ANTICANCER EVALUATION OF Palythoa tuberculosa 
 
3.1 Introduction 
The literature indicates that P. tuberculosa possesses several highly toxic compounds to 
both animals (Wiles et al., 1974) and humans (Uemura, 1991), with marked cytotoxic 
effects (Quinn et al., 1974). Based on this, the study aims to evaluate the anticancer 
activity of this zoanthoid on several human cell lines which can be later exploited in 
treatment of cancer. This chapter entails evaluating the cytotoxic effects of three of the 
isolated novel compounds; palysterols B, C and G, and the known compound palysterol 
A isolated from P. tuberculosa. The anticancer evaluation was done on three cancer cell 
lines namely; MCF-7 (human breast adenocarcinoma), HeLa (human cervical 
carcinoma), HT-29 (human colon adenocarcinoma) and one non-cancerous human cell 
line KMST-6 (fibroblast) via colorimetric in vitro assay. Although several compounds 
were isolated from P. tuberculosa in this study, yet the anticancer evaluation was limited 
to those compounds isolated in significant amounts. The continuous understanding of the 
apoptotic pathways, and its relation with the progression of cancer in the body generated 
the drive to identify therapeutic agents that specifically induce cell death via apoptosis. 
Pro-apoptotic agents are expected to act specifically on tumour cells with minimal 
toxicity on normal cells (Nagle et al., 2004), and consequently induce less side effects. 
Thus, this chapter also discusses preliminary work towards understanding the mode of 
action of the cytotoxic agents, by evaluating the potential of the compounds to induce 
apoptosis in cultured human cancer cells.  
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3.2 Materials  
 
3.2.1 General reagents 
 
Chemical                                                                                          Supplier 
 
C2-Ceramide...................................................................................  Calbiochem 
Dulbecco’s modified Eagle’s medium (DMEM)...........................  Lonza 
Dimethyl sulfoxide (DMSO).......................................................... Sigma      
Foetal bovine serum (FBS)............................................................. Thermo Scientific  
Penicillin-streptomycin...................................................................  Lonza 
Phosphate buffered saline (PBS).................................................... Lonza 
Trypan blue stain 0.4%...................................................................  Invitrogen 
Trypsin............................................................................................ Gibco 
 
3.2.2 Commercial kits 
 
Apoptosis Kit – Annexin V Alexa Fluor® 488...............................  Molecular probes 
Cell proliferation reagent (WST-1)................................................  Roche 
 
3.2.3 Instruments  
 
12 well multiwell culture plates..................................................... Nest biotechnology  
24 well multiwell culture plates.....................................................   Sigma-Aldrich  
96 well multiwell culture plates.....................................................  Sigma-Aldrich 
Cell Culture flasks 25 cm
2
.............................................................  SPL Life Sciences 
Centrifuge 5417R........................................................................... Eppendorf AG   
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CO2 Incubator................................................................................  Shellab 
Countess™ automated cell counter................................................  Invitrogen  
Countess™ cell counting chamber slide........................................  Invitrogen  
POLARstar Omega microplate reader...........................................  BMG Labtech 
Sorvall TC-6 centrifuge................................................................. Sorvall 
Tali
® 
cellular analysis slides..........................................................  Invitrogen 
Tali
®
 Image-Based Cytometer............................................................. Invitrogen 
3.3 Cell culture  
All cells (Table 3.1) were cultured in DMEM medium containing foetal bovine serum 
(10% v/v) and antibiotic (1% v/v). 
 
Table 3.1:  Cell lines used in this study. 
 
Cell Line Cell type Species Origin Growth 
Medium 
 
Hela Cervical 
adenocarcinoma 
          Human       DMEM  
 
HT-29  
 
Colon 
adenocarcinoma 
 
Human 
 
DMEM 
 
 
KMST-6 
 
Fibroblast 
 
Human 
 
DMEM 
 
 
 
MCF-7  Breast 
adenocarcinoma 
Human DMEM . 
 
Cryogenic vials containing the cells were taken from the -150ᵒC fridge and slowly 
thawed to 37ᵒC. The cells were plated into 25 cm2 flasks and cultured in humidified CO2 
incubator (5% CO2) at 37ᵒC until confluency was reached. The culture medium was 
replaced every 48 hr. 
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3.3.1 Trypsinization of cells 
 
After reaching 90% of confluency, the culture medium was discarded and cells were 
washed with 5 mL PBS and 2 mL of pre-warmed trypsin was added for the purpose of 
trypsinization.  The flasks were incubated at 37ᵒC until cells detached from the bottom of 
flasks. Two volumes of growth medium were then added to deactivate the action of 
trypsin and the mixtures were transferred into sterile 15 mL centrifuge tubes. The tubes 
were then centrifuged at 2500 rpm for three minutes using Sorvall TC6 centrifuge at 
room temperature and the cell pellets were recovered after discarding the supernatant.  
The cell pellets were either re-suspended in growth medium or growth medium 
containing 10% DMSO depending on whether the cells were going to be seeded into new 
flasks or whether the cells are going to be stored at -150ᵒC. 
 
3.3.2 Storage of cells  
 
After attaining the cells pellets after trypsinization as mentioned in section 3.3.1, the cells 
pellets are re-suspended in growth medium containing 10% DMSO. The suspension was 
then transferred to labelled cryogenic vials and stored at -150ᵒC. 
 
3.3.3 Counting of cells 
 
Cell counts were performed as per the manufacturer’s instructions using Countess™ 
automated cell counter (Invitrogen). 
3.4 Preparation of stock solutions of the compounds  
The compounds were weighed and dissolved in DMSO. Then the compounds were 
diluted in complete growth medium to reach concentration of 1000 μg/mL of each 
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compound in growth medium. The final concentration of DMSO after dilution was 1% in 
100 μl. 
3.5 Evaluation of the effects of treatments on the morphology of cells 
All cells (listed in Table 3.1) were monitored for their confluence using Nikon inverted 
light microscope. In order to document the morphological characteristics of treated and 
untreated cells, cells were cultured in 24 well multiwell culture plates to 90% confluence. 
The cells were treated with palysterols B and G at a concentration equivalent to their IC50 
values. The negative control cells were left untreated. The plate was incubated at 37 ᵒC in 
a humidified CO2 incubator. After 24 hours, the cells were photographed at 20X 
magnification using Leica EC3 digital camera. 
3. 6 Cell proliferation assay (WST-1) method  
The growth inhibitory effects of the methanolic extract of P. tuberculosa and some of the 
isolated compounds were evaluated using the tetrazolium salt WST-1 colorimetric assay, 
as recommended by the manufacturer (Roche Diagnostics GmbH, Mannheim, Germany) 
(Liu et al., 1995). The cells were cultured to 90% confluence and trypsinized as described 
in sections 3.3 and 3.3.1. The cells were seeded in a 96-well multiwell culture plates at a 
density of 2.0 x 10
4 cells/100μL per well. The plates were incubated at 37 ᵒC in a 
humidified CO2 incubator for 24 hours, then the culture medium was removed and the 
cells were treated with increasing concentrations (12.5, 25, 50, 75 and 100 μg/mL) (The 
micro molar concentrations for the isolated compounds could not be calculated, since the 
molecular weights of the compounds were not yet known at the time of anticancer 
evaluation) of the total extract or the isolated compounds. As a positive control, the cells 
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were treated with 200 µM C2-Ceramide, a known inducer of apoptotic cell death (Obeid 
et al., 1993). Since DMSO is known to be toxic to cells (Da Violante et al., 2002), an 
additional control was set up to evaluate its toxicity. The cells were therefore also treated 
with 1% DMSO. Untreated cells were used as a negative control. All treatments were 
done in triplicate. After 24 hours, WST-1 reagent was added (10 μL) to the wells, and the 
plates were incubated at 37 ᵒC for another four hours. The optical density/absorbance of 
the wells was determined using a BMG Labtech POLARstar Omega microplate reader, 
the plates were read at 430 nm, and 630 nm was used as a reference wavelength. The 
percentage of cell viability was calculated by comparing the absorbance of the test 
samples with the absorbance of the control (untreated) samples using the following 
calculation:    
% 𝐂𝐞𝐥𝐥 𝐕𝐢𝐚𝐛𝐢𝐥𝐢𝐭𝐲 =
𝐬𝐚𝐦𝐩𝐥𝐞 𝐚𝐛𝐬𝐨𝐫𝐛𝐚𝐧𝐜𝐞 − 𝐜𝐞𝐥𝐥 𝐟𝐫𝐞𝐞 𝐬𝐚𝐦𝐩𝐥𝐞 𝐛𝐥𝐚𝐧𝐤 
𝐜𝐨𝐧𝐭𝐫𝐨𝐥 𝐚𝐛𝐬𝐨𝐫𝐛𝐚𝐧𝐜𝐞
 × 𝟏𝟎𝟎 
 
The selectivity index (SI) of the compounds was calculated according to the following: 
 
𝐒𝐈  =   
𝐓𝐡𝐞 𝐡𝐚𝐥𝐟 𝐦𝐚𝐱𝐢𝐦𝐚𝐥 𝐢𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫𝐲 𝐜𝐨𝐧𝐜𝐞𝐧𝐭𝐫𝐚𝐭𝐢𝐨𝐧 of KMST-6
𝐓𝐡𝐞 𝐡𝐚𝐥𝐟 𝐦𝐚𝐱𝐢𝐦𝐚𝐥 𝐢𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫𝐲 𝐜𝐨𝐧𝐜𝐞𝐧𝐭𝐫𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐚𝐧𝐲 𝐜𝐞𝐥𝐥 𝐥𝐢𝐧𝐞
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3.7 Annexin V apoptosis assay 
This assay was done as described by the manufacturer (Invitrogen). In brief, the cells 
were seeded in 24-well multiwell culture plate at concentration of 2.0 x 10
5 cells/500μL 
per well, then the plate was incubated at 37 ᵒC in a humidified CO2 incubator for 24 
hours. After removing the media from the wells, the cells were then treated with a 
concentration equivalent to the IC50 values for the selected compounds for 24 hours. The 
cells were also treated with 100 µM C2-ceramide as positive control, while negative 
control cells were left untreated. Following the 24 hours treatment, the cells were 
recovered by gentle trypsinization as described in section 3.3.1. The cell pellet was re-
suspended in 100 μL 1X Annexin binding buffer (ABB) and transferred to 1.5 mL 
Eppendorf tubes, then 5 μL of Annexin V was added to each sample and mixed well. The 
cell suspensions were incubated in the dark. After 20 minutes, the samples were 
centrifuged at 3500 rpm for 3 min using Centrifuge 5417R, the cell pellets were re-
suspended in 100 μL of 1X Annexin binding buffer. Propidium iodide (1 μL) was added 
to each sample and mixed. The cells were incubated for 5 min and 25 μL of each sample 
was transferred to Tali
® 
cellular analysis slides. Fluorescence resulting from either 
Annexin V or PI uptake was analyzed by Tali
® 
Image-Based Cytometer using apoptosis 
settings. 
3.8 Statistical analysis 
The data presented are means ± SD obtained from at least three independent experiments. 
Differences between the means were considered to be significant if p < 0.05 according to 
Prism’s two-way ANOVA. All calculations were performed using MS Excel 2007.  
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3.9 Results  
 
3.9.1 Evaluating the cytotoxic effects of the total extract of P. tuberculosa 
 
Four human cell lines (KMST-6, MCF-7, HeLa and HT-29) were treated for 24 hours 
with the total methanolic extract of P. Tuberculosa as described in section 3.6. The cell 
viability following treatment was determined using WST-1 assay. The results (Figure 
3.1) show a dose dependent decrease in the viability of the cells.  The viability of all cell 
lines was unaffected at 12.5 μg/mL, while no viability was observed at the highest dose 
of 100 μg/mL. KMST-6 cells showed more resistance to the effect of the lipophilic 
extract as its viability was only affected at the highest concentration (100 μg/mL). 
Evidently, at concentration of 75 μg/mL the KMST-6 cells showed significant (p<0.001) 
viability compared to other cancerous cell lines. At concentrations of 25 and 50 μg/mL, 
HeLa and MCF-7 cells appeared to be more susceptible to the effect of the lipophilic 
extract. HeLa was most affected (p<0.001) compared to other cell lines at concentration 
25 μg/mL, while MCF-7 was most susceptible (p<0.001) at 50 μg/mL compared to 
KMST-6 and HT-29.  
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Figure 3.1: The effect of the total methanolic extract of P. Tuberculosa on the cell viability of HeLa, HT-
29, MCF-7 and KMST-6 as determined by the WST-1 assay. 
*** Statistical significance of (p<0.001) compared to data labelled with the same letter.  
 
 
 
 
3.9.2 Evaluating the cytotoxic effects of the isolated compounds 
 
Although several compounds were isolated from P. Tuberculosa in this study only four 
palysterols A, B, C and G were selected to assess if these compounds have any cytotoxic 
effects on KMST-6, MCF-7, HeLa and HT-29 cells. The cells were treated for 24 hours 
with the four compounds as described in section 3.6 and cell viability was assessed using 
the WST-1 assay. The IC50 and SI values for these compounds were determined (Table 
3.2). Palysterols A and C did not demonstrate any cytotoxicity effects in the four cell 
lines used in this study. Palysterol G, however, was the most toxic compound with 40, 59, 
61, and 62 μg/mL (= 82, 122, 126 and 128 μM) for MCF-7, HT-29, HeLa and KMST-6 
cells, respectively. Palysterol B demonstrated selective toxicity towards HT-29 and MCF-
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7 cells with IC50 values of 83 and 87 μg/mL (170 and 178 μM), respectively. This 
compound was not toxic towards HeLa and KMST-6 cells and therefore the SI for 
palysterol B in MCF-7 and HT-29 could not be accurately determined.   
 
Table 3.2: IC50 (μg/mL) and SI values for palysterols A, B, C and G as determined by WST-1 
assay. 
 
 
 
Compounds 
Cell Lines 
 
MCF-7 
 
HeLa 
 
HT-29 
  
KMST-6 
 
IC50 
 
SI 
 
IC50 
 
SI 
 
IC50 
 
SI 
  
IC50 
 
Palysterol A 
 
> 100 
 
---- 
 
> 100 
 
---- 
 
> 100 
 
---- 
 
 
 
> 100 
 
Palysterol B 
 
87 
 
>1.1 
 
> 100 
 
---- 
 
83 
 
>1.2 
 
 
 
> 100 
 
Palysterol C 
 
> 100 
 
---- 
 
> 100 
 
---- 
 
> 100 
 
---- 
 
 
 
> 100 
 
Palysterol G 
 
40 
 
1.6 
 
61 
 
1.0 
 
59 
 
1.1 
 
 
 
62 
 
 
3.9.3 Evaluating the apoptotic activity of the isolated compounds 
 
Only palysterols B and G were selected for this assay as they showed higher cytotoxic 
activity compared to palysterols A and C. The lowest IC50 concentrations as determined 
by the WST-1 assay of both compounds were used i.e. 82 μM for palysterol G and 170 
μM for palysterol B. These concentrations were used to determine if both compounds can 
induce apoptosis in cancer cells. The four cell lines were treated with the two compounds 
and the level of apoptosis was assessed using the Annexin V apoptosis assay as described 
in section 3.7. The result showed that only palysterol G was able to induce significant 
levels of apoptosis (Figure 3.2). The compound significantly (p<0.001) induced apoptosis 
in MCF-7 cells compared to the other cell lines used. Palysterol G induced apoptosis in 
about 75% of MCF-7 cells. Also, palysterol G exhibited low cytotoxic activity on 
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KMST-6 cells (p<0.05) when compared to the negative control. Apoptosis induction was 
also observed under the microscope for both compounds. Notably, palysterol G was 
showing high count of apoptotic cells in MCF-7 cells (Figure 3.3). 
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Figure 3.2: Percentage of live, dead and apoptotic cells induced by palysterols B and G on KMST-6, MCF-                            
7, HeLa and HT-29 cell lines. 
a*: statistical significance (p<0.05) of palysterol G compared to negative control in KMST-6. 
b***: statistical significance (p<0.001) for palysterol G compared to palysterol B, negative and positive 
controls.  
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                     Negative control                                                                        Positive control 
                       
 
 
 
                          Palysterol G                                                                            Palysterol B 
                        
 
Figure 3.3: Photographss showing the apoptotic effect of the two compounds, palysterols B and G on 
MCF-7 cells showing apoptotic cells (yellow arrows). Notably, apoptotic cells covering the field of MCF-7 
when treated with palysterol G. The morphological appearance of the labelled cells depicts the description 
of apoptotic cells by Lawen (2003), who stated that cells during early apoptosis become rounded up, shrink 
and lose contact with their neighbouring cells (Lawen, 2003) . 
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3.10 Discussion 
Polyhydroxysterols or oxysterols are suggested to be potent cell replication inhibitors, 
and may have a role in regulation of cell proliferation, thus, are considered to have the 
potential to treat cancer (Sarma et al., 2009). In this study, palysterols B and G were 
found to be the more cytotoxic amongst the compounds tested. Palysterol G showed high 
activity against breast adenocarcinoma cells (MCF-7) with an IC50 value of 82 μM, while 
palysterol B demonstrated highest cell death on colon adenocarcinoma cell line (HT-29) 
with IC50 = 170 μM. Palysterol G exhibited some degree of selectivity against cancerous 
cell lines, showed by results obtained by both WST-1 and Annexin V apoptosis assays.  
 
The WST-1 assay measures cell viability as a function of the cell’s metabolic activity. 
There are several different types of cell death that can lead to loss of cell viability as 
discussed in section 1.1.3.7. Apoptosis is one of these types of cell death and plays a key 
role in the prevention of cancer. One of the characteristics of cancer cells is their 
resistance to apoptosis (Hanahan and Weinberg, 2000). The targeted activation of 
apoptosis in cancer cells is therefore a feasible therapeutic strategy to treat cancer. It is 
for that reason that we also investigated if the cytoxicity of these compounds was due to 
the activation of apoptosis. We found that palysterol B did not induce significant 
apoptosis levels in any of the cell lines tested in this study, while palysterol G induced 
significant (P<0.001) levels of apoptosis in MCF-7 cells, but not in any of the other cell 
lines.  
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There are many assumptions with regards to structural activity relationship of oxysterols. 
The nature side chain is suggested to play a key role in determining the activity of the 
oxysterols (Liu et al., 2013). This comes in agreement with our findings, as the 
unsaturation at ∆22 which is present only in palysterol G may greatly contribute to its 
activity, in fact, it is the only structural difference between palysterol G and the inactive 
palysterol C. Besides the side chain effect, the nature of substituent in C18 may also has 
an effect on the cytotoxicity [CHO in palysterol G > CH2OH (palysterol B) > CH3 
(palysterol A)]. In addition, the acetylation of 1-OH may also play role in the cytotoxicity 
[OAc (palysterol G) and (palysterol B) > OH (palysterol A)], which was also suggested 
by Liu and co-workers (2013).  
 
Many oxysterols were found to act as pro-apoptotic in various in vitro systems, yet a 
universal mechanism by which these metabolites use to induce apoptosis remains to be 
clarified (Lordan et al., 2009). In their article, Lordan and co-workers, stated that the 
apoptotic studies of the polyhydroxylated sterols revealed that apoptosis was mainly 
triggered using intrinsic pathways, though little proof of activation of the death receptor 
pathway was established (Lordan et al., 2009). Morrissey and Kiely (2006) suggested 
that pro-apoptotic action of oxysterols might be due to an increase in intracellular levels 
of reactive oxygen species (ROS), altering several signalling pathways and gene 
expression or by the induction of cell proteins modification. Furthermore, Olkkonen and 
Hynynen (2009) stated that common oxysterols are mostly known to interfere with cell 
membrane structure and cellular receptors. From the above, it is recommended that more 
mechanistic assays, such as Intracellular ROS, caspase 3/7 and 9 measurements and 
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topoisomerase inhibition determination, should be done in order to determine which 
apoptotic pathway is activated by palysterol G.  
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